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Abstract
N eurotrophins are  trophic  and m itogenic proteins th a t play a role 
in th e  d eve lo p m en t, d iffe ren tia tio n , connectivity and survival of 
neurons, acting via th e ir  specific receptors in the  central and 
peripheral nervous system , including the retina. The preferred  
receptor fo r brain derived  neurotrophic factor (B D N F) and
neurotrophin 4 (N T 4 ) is TrKB. M uller cells m ay play an im po rtan t 
role in neurotrophin function in the  nervous system . I t  has been
suggested th a t neurotrophins e xert th e ir effects on
photoreceptors by acting indirectly  through activation of Muller 
cells.
The aim s of the  present w ork w ere to characterise the
expression of BDNF, N T4 and TrkB  by hum an M uller cells in 
vitro , and to exam in e  w h e th e r changes in the  expression of 
these m olecules occur in retina  from  patients with pro liferative  
v itreo retin o p ath y  (PVR ) w hen com pared with norm al retina. In  
addition , changes in th e  expression of BDNF, NT4 and glial 
fib rillary  acidic protein  (GFAP) w ere also investigated in 
m elanom a affected  hum an retina following laser 
photocoagulation.
A va rie ty  o f techniques w ere em ployed to investigate the  
expression o f th e  above neurotrophins and TrkB  a t the  RNA and 
protein levels. These included cell culture and mRNA extraction ,
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RT-PCR, W estern blot, and Im m unocytochem istery. Confocal 
laser scanning m icroscopy and light microscopy w ere  used for 
im aging.
The results showed th a t cultured hum an M uller cells express  
BDNF and NT4 as indicated by both mRNA and protein  
expression. A truncated  isoform of TrkB was also shown to be 
expressed by a spontaneously im m ortalized hum an M uller cell 
line used in the  study (M IO -M l) .
Staining for NT4 was greatly  increased in retinal sections from  
eyes w ith PVR, com pared with norm al retina. NT4 expression by 
M uller cells in situ  was confirm ed by confocal imaging  
observations th a t cells staining for this neurotrophin co-stained  
for GFAP. By contrast, th ere  was a decrease in TrkB  
im m unostain ing in PVR retinectom y sections com pared with  
controls. NT4 staining was also reduced a t the site of laser burns 
in m elanom a affected retina. Possible explanations are discussed 
in the  thesis.
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Chapter 1 
Introduction
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1.1 Retinal cells and structure
The retina (Latin: rete = net) is the internal layer of the eyeball. It is a thin 
delicate layer of nervous tissue that varies in thickness in different regions 
from about 0.1 mm at the most peripheral area (ora serrata) to 0.56 mm 
near the optic disc. Its thickness at the equator is 0.18mm (Sigelman J 
and Ozanics V1982; Tripathi RC and Tripathi BJ 1984; Ogden T 1989a 
and b). The surface area of the retina is approximately 266 mm2. The 
central area of the retina (area centralis) is divided into the fovea and the 
foveola. The fovea is approximately at the centre of the area centralis and 
has a thickness of 0.25 mm and a diameter of 1.85 mm. It is located 4 mm 
temporal to the optic disc and about 0.8 mm below the horizontal 
meridian. The Foveola is located at the central part of the fovea and 
recognised by the concave indentation produced by its thinner structure. It 
measures 0.13 mm in thickness and 0.35 mm in diameter and is 
composed solely of cone photoreceptors. The macula lutea is about 3mm 
in diameter and is an oval, yellowish area, in the central retina. The yellow 
appearance is probably due to the presence of xanthophylls (a carotinoid 
pigment) in the ganglion and bipolar cells.
The retina has a highly organised structure and histologically has two 
main components: a pigmented layer and a sensory layer derived from the 
outer and the inner layers of the embryonic optic vesicle respectively. As 
seen in cross-section histologically, the retina is composed of 10 layers 
which from the outer to the inner aspect are: retinal pigment epithelium 
(RPE), photoreceptor layer of rods and cones, external limiting membrane,
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outer nuclear layer, outer plexiform layer, inner nuclear layer, inner 
plexiform layer, ganglion cell layer, nerve fibre layer and inner limiting 
membrane.
At the fovea only the following layers are present: RPE, cone 
photoreceptors, the external limiting membrane, the outer nuclear layer, 
the inner fibres of the photoreceptors (Henle’s fibre layer) and the internal 
limiting membrane.
The retinal pigment epithelium (RPE) has many important roles in the 
normal visual process including maintaining adhesion of the neurosensory 
retina, phagocytosis of the photoreceptor outer segments, improving 
image resolution by light absorption, transport and storage of metabolites 
and providing a permeable barrier between the choroid and the 
neurosensory retina.
The neurosensory retina consists of several cell types that form three 
layers of nerve cell bodies and two layers of synapses. Retinal cell types 
are divided between a population of non-neuronal cells including vascular 
endothelial cells, pericytes, and glial cells and neuronal cells including 
photoreceptors, horizontal and amacrine cells, bipolar cells and ganglion 
cells.
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Figure 1.1 Layers of normal human retina (from Ghazi-Nouri SM et a l 2003). 
RPE=retinal pigment epithelium, PR=photoreceptor layer of rods and 
cones, OLM=outer limiting membrane, ONL=outer nuclear layer, 
OPL=outer plexiform layer, INL=inner nuclear layer, IPL=inner plexiform 
layer, GCL=ganglion cell layer, NFL=nerve fibre layer.
Neurones are the predominant cells in the retina. The light impulses are 
relayed by the photoreceptors, bipolar cells and ganglion cells and are 
transmitted to the brain via the ganglion cell axons in the optic nerve.
The outer nuclear layer contains cell bodies of the rods and cones, the 
inner nuclear layer contains cell bodies of the bipolar, horizontal, Muller 
and amacrine cells, and the ganglion cell layer contains cell bodies of 
ganglion cells and displaced amacrine cells. The outer and inner
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plexiform layers (OPL and I PL) are where the synaptic contacts occur. In 
the OPL connections between rod and cones, and vertically running 
bipolar cells and horizontally oriented horizontal cells occur. The IPL 
functions as a relay station for the vertical-information-carrying nerve cells, 
the bipolar cells, to connect to ganglion cells.
1.2 Glial cells of the retina
There are three basic types of glial cells in the retina; astroglia, microglia 
and Muller cells as outlined below.
1.2.1 Retinal astrocytes
Astrocytes, named for their stellate shape, are not glial cells of the retinal 
neuroepithelium but are believed to enter the developing retina from the 
brain along the developing optic nerve (Stone J and DreherZ 1987, Chan- 
Ling T 1994). Their characteristic morphology includes a flattened cell 
body and a fibrous series of radiating processes. They express glial 
fibrillary acidic protein (GFAP) (Schnitzer J 1988) and their cell bodies are 
almost entirely restricted to the nerve fibre layer of the retina. The 
distribution of retinal astrocytes is determined by the retinal vasculature 
(StoneJ and Dreher Z 1987). Astrocytes are more prominent on the optic 
nerve head and are absent in the avascular fovea or ora serrata. 
Astrocytes are arranged over the surface of the ganglion cell axon bundles 
as they enter the optic nerve head. The blood vessels running in and 
among the ganglion cell bundles are also covered by both processes and 
occasional cell body of an astrocyte. This arrangement suggests that
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astrocytes are axonal and vascular glial sheaths and part of a blood-brain 
barrier. They contain glycogen and may provide glucose to the neurons.
1.2.2 Retinal microglial cells
Microglial cells are found in every layer of the retina and are of
mesodermal origin (unlike Muller cells and astrocytes which are derived 
from the neuroectoderm). They have small cell bodies with a thin
cytoplasmic rim around the nucleus and irregular short processes that 
often encircle retinal capillaries (Vrabec F 1970). The distribution of 
microglia is believed to be related to the pattern of cell death at different 
stages of retinal development (Hume DA 1983). In several mammals 
studied inclung in the monkey, the retinal microglia are usually seen in 
association with the retinal vasulature and are found in all retinal layers 
from the margin of the inner retina to the outer plexiform layer (Verbec F 
1970). In the rat however the distribution of the retinal microglia is
somewhat different with microglial cells found throughout the thickness of
the retina during the embryonic stage but only seen in the inner half of the 
retina in the differentiated stage (Ashwell KW1989).
Retinal microglial cells are analogous to the histiocytes of the central 
nervous system, exhibiting similar phagocytic properties in response to 
injuries (Potts RA 1982, Ling EA 1982, Hume DA 1983, Ashwell KW 
1989). In normal human retina, microglial cells are normally in a resting 
state but may become activated by nerve degeneration, inflammation and 
traumatic nerve lesions and can play an important role in
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immunoregulation and tissue repair, neurodegeneration, autoimmune 
disease, vitreoretinopathy, diabetic retinopathy, glaucoma and age related 
macular degeneration (Chen L 2002).
1.2.3 Miiller cells
Muller cell functions are summarised in table 1.1. Muller cells are 
specialised glial cells of the retina. They are found in all retinal regions, 
except optic nerve head, of all vertebrates studied. Muller cells were first 
described by Heinrich Muller (1820-1864), who was professor of 
topographical and comparative anatomy at Wurzburg, Germany, in an 
article entitled “On the Histology of the Retina”, published on 15th May 
1851 (Sarthy V and Ripps H 2001).
In the mammalian retina there are about 106 to 107 Muller cells (Robinson 
SR and Dreher Z 1990, Dreher Z 1992, Reichenbach A and Robinson SR 
1995, Distler C and Dreher Z 1996) and their morphology varies 
depending on their retinal location. Those at the periphery tend to appear 
shorter with broader end feet and have lower density compared to cells 
located centrally (Uga S 1974, Rasmussen KE 1974, Dreher Z 1988, 
Gauer VP 1988, Reichenbach A 1989, Robinson SR and Dreher Z 1990). 
Muller cells span the entire thickness of the retina from the inner limiting 
membrane to the outer limiting membrane, which consists of junctional 
processes of Muller cells and photoreceptors. Muller cells are in direct and 
close relation with all retinal cell types. Their nuclei are usually located in 
the middle of the inner nuclear layer (Dowling JE 1987).
Muller cells are responsible for the structural stabilisation of the retina and 
provide an orientation scaffold. They are responsible for maintaining the
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layered arrangement of the retinal neurons and are also involved in ion 
homeostasis and glutamate recycling mechanism in the retina. There is a 
strong expression of K+ channels on their plasma membrane, especially of 
inwardly rectifying K+ (Kir) channels, that makes the plasma membrane of 
Muller cells highly permeable to K+ (Brew H 1986, Nilius B 1988, Newman 
EA 1993, Ishii M 1997). This is an important role as removal of extra­
cellular K+ is crucial for normal retinal function. Active neurons release K+ 
which is then redistributed by Muller cells into the subretinal space, blood 
vessels and the vitreous (Newman EA 1984, Karwoski CJ 1989, 
Reichenbach A 1992). Vitreous (and blood) is a main sink for the K+ 
redistribution and it has been suggested that a certain minimal volume of 
vitreal fluid is essential for efficient buffering of intraretinal increases of 
potassium ions through the Muller cells. Replacing the vitreous with a 
medium that is not capable of dissolving K+ (such as perfluorocarbon liquid 
or silicone oil) may cause long-lasting accumulation of potassium ion and 
consequent neurodegenerative and reactive gliosis occurs (Winter M 
2000).
Muller cells exert their important role in survival of neurones not only by 
removal of metabolic waste, but also by providing trophic factors (Poitry S 
2000). Muller cells produce lactate by metabolising glucose. Neurones 
take up lactate for their oxidative metabolism (Poitry-Yamate CL 1995). 
Photoreceptor apoptosis, retinal degeneration and proliferation of retinal 
pigment epithelium (RPE) can occur as a result of selective Muller cell 
death (Dubois-Dauphin M 2000).
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Function References
Glucose uptake and metabolism 
and release of metabolites for 
neuronal use
Magistretti PJ 1999, Mantych GJ 
1993, W atanabeT 1994
Glutamate metabolism Riepe RE and Norenberg MD 
1997, Pow DV 1994
GABA metabolism Hyde JC and Robinson N 1974
Acid-base regulation Musser GL and Rosen S 1973
Retinoid metabolism Bunt-Milam AH and Saari JC 
1983, Saari JC 1978, 1982, Bok D 
1984
K regulation Newman EA 1984, Karwoski CJ 
1989, Reichenbach A 1992
NO synthesis Kobayashi M 2000, Roth S 1997, 
Goureau 0  1999, Koeberle PD 
1999
Neurotrophic factors release and 
supporting ganglion cell survival
Meyer-Frank A 1995, Raju TR and 
Bennett MR1986, Garcia M 2002
Table 1.1 Functions of Muller cells in relation to their metabolic interactions 
with neurons.
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Various growth factors are known to be produced by these cells including 
vascular endothelium growth factor (VEGF) (Jingjing L 1999, Eichler W  
2000) which is a major factor implicated in retinal neovascularisation 
observed in disorders such as diabetic retinopathy, retinopathy of 
prematurity, choroidal neo-vascularisation, and following retinal vein 
occlusion.
Muller cells are also responsible for removal of extracellular glutamate, 
which is the major retinal neurotransmitter and is also toxic to neural cells 
at high concentration. They exert this function by producing the enzyme 
glutamine synthetase responsible for the conversion of glutamate into 
glutamine within Muller cells. Glutamate can be detected within Muller 
cells at an increased level when glutamine synthetase is experimentally 
inhibited (Pow DV and Robinson SR 1994). There is a reduction of this 
enzyme’s activity in Muller cells of detached retina (Erickson PA 1987, 
Lewis GP 1999) leading to disruption of glutamate recycling and 
subsequent glutamate toxicity.
Muller cells can also express nitric oxide synthetase under pathological 
conditions (Kobayashi M 2000). During hypoxia and hypoglycaemia nitric 
oxide (NO) produced by Muller cells may increase the retinal blood flow 
(Roth S 1997). The NO synthesised by activated Muller cells can induce 
neuronal cell death although it is not known to be toxic to the Muller cells 
themselves (Goureau O 1999, Koeberle PD 1999).
It has been shown that release of neurotrophic factors from glial cells 
support the survival of ganglion cells in culture (Meyer-Franke A 1995). In 
rats Muller cell conditioned medium has been shown to support survival of
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ganglion cells at birth but not at 6-day postnatal stage (Raju TR and 
Bennett MR 1986). In pigs however the protective role of Muller cell has 
been observed even in adult animals’ cells in culture (Garcia M 2002).
1.3 MIO/M1 Cell line
Availability of a cell line for in vitro studies is a valuable tool for a better 
understanding of various aspects of cellular functions. In vitro 
investigations of Muller cell functions have been laborious due to tendency 
of these cells to differentiate rapidly in culture and therefore difficulty in 
obtaining pure cell population (Sarthy VP 1998). Previous Muller cell lines 
reported in the literature have been obtained from the rat retina (sarthy VP 
1998, Roque RS 1997). Recently a human Muller cell line has been 
characterised (Limb GA 2002) and named MIO-M1, after the institutions 
where it was isolated (Moorfields, Institute of Ophthalmology-Muller 1). 
MIO-M1 cells are spontaneously immortalized cells expressing well known 
markers of Muller cells including epidermal growth factor receptor (EGF- 
R), glutamate synthetase, cellular retinaldehyde binding protein 
(CRALBP), ^-smooth muscle actin (^-SMA), and vimentin but not glial 
fibrillary acid protein (GFAP). GFAP expression in mammalian Muller cells 
is at low level or may be absent (Bignami A 1979, Lewis GP 1994), and it 
inceases in culture (McGillem GS 1998) and in pathological conditions 
such as injury (Lewis GP 1994, Hollander H 1991). Lack of GFAP 
expression by cultured MIO-M1 cells suggests these cells do not exhibit 
characteristics of activation.
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In addition to expressing the above cell markers MIO-M1 cells have 
morphologic appearance under phase contrast and transmission electron 
microscopy consistent with those reported in the literature for glial Muller 
cells (Limb GA 2002).
Both astrocytes and Muller cells have the potential to express GFAP. 
Muller cells also express CRALBP but astrocytes do not (CRALBP is also 
expressed by RPE cells). It is therefore possible to differentiate between 
these two glial cells by employing both of these markers.
Figure 1.2 Scanning electron micrograph of a MIO-M1 cell (Courtesy of Dr 
Astrid Limb).
Scale bar=5pm
1.4 Retinal disorders associated with Muller cell dysfunction
Retinal disorders associated with Muller cell dysfunction are listed in the 
table 1.2. Dysfunction of Muller cells has been associated with a number 
of retinal disorders. These include X-linked retinoschisis, retinal gliosis in 
proliferative vitreoretinopathy (PVR) and epiretinal membrane (ERM), 
Muller cell sheen dystrophy, cystoid macular oedema, idiopathic macular 
hole formation and retinal neovascularisation.
Retinal Disorder Reference
X-linked juvenile retinoschisis 
Cystoid macular oedema 
Muller cell sheen dystrophy
Harris GS and Yeung J 1976, 
Condon GP 1986
Fine BS 1981, Yanoff M1984,
Loeffler KU 1992
Polk TD 1997, Kellner U 1998
Retinal detachment Fisher SK 1994, Korte GE 1992
Retinal membranes/PVR Guerin CJ 1990, Kono T 1995
Macular hole Gass D 1999
Neovascularisation Pierce EA 1995
Table 1.2 Retinal disorders associated with Muller cell dysfunction.
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1.4.1 X-linked juvenile retinoschisis
This is an X-linked disease (affecting males and carried by females) first 
described by Haas in 1898 (Haas J 1898) and is a relatively rare 
vitreoretinal dystrophy. Its worldwide prevalence is between 1:15,000 to 
1:30,000 (de la Chapelle A 1994) and causes bilateral splitting of the 
retina (retinoschisis) often involving the macula (foveomacular schisis). 
The mutuation responsible for human X-linked retinoschisis has been 
identified and the gene codes for retinoschisin, which is expressed in 
photoreceptor and bipolar cells and is probably not related to Muller cells. 
Retinoschisin is a secreted protein containing a discoidin domain, which 
may be involved in cellular adhesion or cell-cell interactions (Tantri A 
2004).
The exact pathogenesis of the condition is unknown however there are 
reports of an inherited defect and involvement of Muller cells in the 
pathogenic mechanism of the disease has been proposed (Yanoff M 
1968, Manschot WA 1972, Condon GP 1986, Peachey NS 1987). Condon 
et al (Condon GP 1986) found intreretinal filaments produced by the 
defective Muller cells and proposed that their extracellular accumulation 
may lead to degeneration of cells and schisis formation. Retinoschisin has 
been shown to be selectively taken up and transported by Muller cells into 
the inner retina (Reid SN and Farber DB 2005). The electroretinogram 
(ERG) findings in affected cases typically show a reduced b-wave and 
normal a-wave. Miyake et al reported a reduction in the a-wave at the later 
stages of the disease (Miyake Y 1993). It is known that Muller cells are 
largely responsible for the b-wave component of an ERG and hence
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Muller cell dysfunction has been suggested to be part of this abnormal 
retinal function. Sauer et al have identified a gene responsible for XLRS 
(called XLRS1 gene) with several mutations being subsequently reported 
(Sauer CG 1997). Japanese juvenile retinoschisis is reported to be caused 
by mutations of the XLRS1 gene (Hotta Y 1998).
Gene analysis in 234 familial and sporadic retinoschisis cases showed 
mutation in 214 cases with 82 different mutations. Despite the enormous 
mutation heterogeneity and regardless of the mutation type, patients had 
relatively uniform clinical manifestations. This and lack of symptoms in 
carriers suggests that retinoschisis is a disease caused by a loss-of- 
function rather than a dominant-negative effect (The Retinoschisis 
Consortium 1998).
Since Muller cells remove K+ from the extracellular space, failure to do so 
will result in raised K+ concentration and a transient white-yellow sheen 
might be seen in the retina (De Jong PT 1991). This phenomenon (known 
as Mizuo-Nakamura phenomenon) has been reported in X-linked 
retinoschisis, providing further support for involvement of Muller cells in 
the pathology of this condition. It has also been suggested that the colour 
changes associated with retinoschisis result from inability of the damaged 
cell end feet to clear K+ from the extracellular space (De Jong PT 1991).
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1.4.2 Cystoid Macular Oedema (CMO)
CMO is associated with a number of retinal conditions including 
retinovascular disease, retinal degeneration, intraocular inflammation, 
tumours, and post cataract surgery. It is thought that the condition is 
related to presence of clear cysts in Henle’s layer and/or to the breakdown 
of blood retinal barrier with accumulation of serous exudates in the retina.
It is unlikely that a single aetiologic factor is responsible for the occurrence 
of CMO in such a wide variety of conditions. The question whether fluid is 
accumulated in extracellular space or within Muller cells is still not clearly 
understood. Some histopathological studies suggested that cystoid 
spaces represent swollen Muller cell processes (Fine BS 1981, Yanoff M 
1984). Muller cell enlargement occurs without much accumulation of 
extracellular fluid suggesting that the primary site of oedema is the Muller 
cell itself (Fine BS 1981). In another more recent histopathologic study on 
the rare genetic condition dominantly inherited cystoid macular oedema 
primary disorder of the Muller cells was suggedted (Loeffler KU 1992). 
Other studies suggest that fluid accumulation is in the extracellular space 
and that neuronal loss and Muller cell changes are secondary events 
(Gass JDM 1985, Tso MOM 1982, Wolter JR 1981).
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1.4.3 Muller cell sheen dystrophy
This is an autosomal dominant condition causing multiple folds at the level 
of the internal limiting membrane (ILM) at the posterior pole of the retina. It 
can lead to macular oedema in some cases and the ERG changes show a 
reduction in the amplitude of the b-wave (Kellner U 1998). Histologically 
there is a diffuse thickening of the ILM, superficial retinal schisis cavities 
and cystoid spaces in the inner nuclear layer (Polk TD 1997). ILM 
thickening and folding has been suggested to be a result of production of 
a protein synthesized and secreted by Muller cells (Kellner U 1998). 
Schisis formation is also thought to be secondary to loss of structural 
support by Muller cells.
Currently there is no effective treatment available. Vitrectomy with 
membrane peel, systemic acetazolamide, non steroidal anti-inflammatory 
drugs (NSAID), steroids and grid laser photocoagulation all have been 
tried in the past but have failed to show a beneficial response (Polk TD
1997).
1.4.4 Retinal detachment and proliferative vitreoretinopathy
In rhegmatogenous retinal detachment (RD) there is a significant 
incidence of proliferative vitreoretinopathy (PVR) occurring in 5% to 10% 
of patients (Machemer R 1991, Asaria RH 2006). PVR is the commonest 
cause of failure of RD surgery and is characterised by cellular proliferation 
affecting both surfaces of the detached neuroretina as well as posterior 
vitreous face and within the vitreous base. These changes will result in
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formation of contractile preretinal membranes. PVR can essentially be 
regarded as a wound healing process in a specialised neuronal tissue.
It is widely accepted that PVR involves a wide variety of cell types. These 
include epithelial cells from the RPE and the ciliary body, macrophages, 
lymphocytes, neutrophils, fibroblastic cells and glia cells including 
astrocytes and Muller cells. Subretinal membranes may take the form of a 
diffuse cell sheet or taut membranes or bands preventing reattachment of 
neuroretina. Diffuse cell sheets have been shown to be formed purely by 
glial cells (Wilkes SR 1987) whereas composition of subretinal bands is a 
mixture of RPE, fibroblasts like cells, macrophages and glia (Wilkes SR 
1987, Trese MT 1985, Schwartz D 1988).
Involvement of glial cells in PVR has been demonstrated in several 
studies (Morino I 1990, Rodrigues MM 1981, van Horn DL 1977, Hiscott 
PS 1984). Glial cells proliferation can contribute to periretinal membrane 
formation. In animal models of RD, Muller cells undergo hypertrophy and 
proliferation within the retina and fill in the space left by dying 
photoreceptors (Lewis GP 2002). In the feline model Muller cells tend to 
grow into the subretinal space forming scars and preventing regeneration 
of photoreceptor outer segment after surgery leading to photoreceptor 
degeneration (Lewis GP 2002).
In PVR and subretinal fibrosis, RPE cells, Muller cells, and astrocytes 
proliferate continuously for weeks or months and migrate onto retinal 
surfaces. During PVR, cells attach to the ILM, proliferate, and form ERM. 
Contraction of this cellular membrane leads to recurrent RD. Muller cells 
have been identified in the ERM (Guerin CJ 1990) and in vitro they have
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the ability to contract (Guidry C 1997, Mamballikalathil I 2000). It is 
therefore possible that Muller cells are involved in the contraction of these 
membranes.
1.4.5 Macular hole
Idiopathic or senile macular hole is a localised circular displacement of 
photoreceptors in the central retina. It affects approximately three in 1000 
individuals resulting in variable reduction of central vision (La Cour M
2002).
It was proposed by Gass (Gass JDM 1999) that the structural support at 
the fovea is provided by a special cone-shaped arrangement of Muller 
cells (Muller cell cone), which serves as a plug to bind together the 
receptor cells in the foveola. Without this arrangement the thin 
photoreceptor cell layer would be susceptible to disruption and hole 
formation which may occur secondary to sensory retinal detachment, 
trauma, cystoid macular oedema, and macular degeneration.
It is also believed that in age-related macular hole formation the tractional 
forces caused by contraction of prefoveolar vitreous cortex, which is firmly 
attached to the internal limiting membrane of the Muller cell cone, is 
responsible for the pathology (Gass JDM 1999,). Similar mechanism ie 
tangential tractional force caused by epiretinal membrane has ben 
proposed in the pathogenesis of lamellar macular holes ERM tangential 
traction may play a role in the pathogenesis of lamellar macular holes 
(G uyerDR 1990).
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1.4.6 Neovascularisation
Retinal neovascularisation is a major cause of blindness worldwide as it is 
associated with disorders such as retinopathy of prematurity, diabetic 
retinopathy, retinal vein occlusion, and subretinal neovascularisation in 
age related macular degeneration. It therefore can affect any age group 
from birth to working age population and the elderly and can lead to loss 
of vision. Hypoxia is a common factor in inducing retinal 
neovascularisation and Muller cells (as well as astrocytes and RPE cells) 
may have a crucial role in the pathogenesis of hypoxia-induced 
neovascularisation.
Vascular endothelium growth factor (VEGF) is a key regulator of normal 
and pathological retinal angiogenesis (Pierce EA 1995). The VEGF family 
is best known for its important roles in regulating the growth of vascular 
and lymphatic endothelia. There are a number of alternatively spliced 
forms of VEGF including variants of 121, 145, 165, 183, 189, and 206 
(Dvorak HF 1999, Houck KA 1991, Tischer E 1991, Yang R 1996). The 
most abundant isoform of VEGF is 165 variant (Houck KA 1991). An 
important biological property differentiating between the VEGF isoforms is 
their heparin and heparan-sulfate binding ability. The 189 and 206 variants 
have enhanced heparin binding due to their structures containing 
stretches of basic residues. This will enable them to anchor to the 
extracellular matrix, while the 121 isoform is freely diffusible (Park JE 
1993). The three secreted VEGF splice isoforms 121, 145 and 165 induce
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proliferation of endothelial cells and in vivo angiogenesis (Poltorak Z 
1997, Park J 1993, Zhang HT 1995). VEGF can be detected in both 
human plasma and serum samples. The detectable levels are higher in 
the serum due to its release from platelets (Banks RE 1998). VEGF 
expression is upregulated during hypoxia and is dependent upon the 
activities of the hypoxia-inducible transcription factors (HIF-1a and HIF-2a) 
(Maxwell P and Salnikow K 2004, Maxwell PH and Ratcliffe PJ 2002).
Low oxygen tension is an important stimulus for retinal VEGF synthesis 
and neovascularisation (Aiello LP 1994) and the release of VEGF by 
cultured Muller cells is increased during hypoxia (Aiello LP 1995, Jingjing 
L 1999, Eichler W  2000). Under normal conditions in the healthy retina, 
Muller cells release anti-angiogenic factors such as pigment epithelium 
drived growth factor (PEDF) and thrombospondin-1, which provide a 
permanent ant-proliferative condition for vascular endothelial cells (Eichler 
W  2004). PEDF is expressed in neurons and glial cells in the retina 
(Aymerich MS 2001, Ogata N 2002, Eichler W 2004) and acts as an anti- 
VEGF. Under conditions of low oxygen tension there is reduced PEDF 
expression in the retina and Muller cells (Duh EJ 2002, Eichler W 2004). A 
PEDF at low level is strongly associated with pregression of diabetic 
retinopathy (Boehm BO 2003). In conditions such as diabetic retinopathy 
and age related macular degeneration (ARMD), Muller cells have shown 
an increased expression of VEGF (Amin RH 1997). VEGF expression in 
Muller cells precedes neovascularisation in the diabetic patients without 
anatomical evidence of retinal malperfusion (Amin RH 1997). This
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suggests that ischemia may not be the sole stimulus for VEGF expression 
in Muller cells (Amin HR 1997).
Furthermore, astrocytes and Muller cells express TGF-beta, which is a 
stimulant for VEGF expression by the Muller cells (Behzadian MA 1998). 
Treatment of cultured rat Muller cells with exogenous TGF-beta increases 
VGEF production both under normoxic and hypoxic conditions (Behzadian 
MA 1998). It is therefore suggested that TGF-beta activation may be 
prerequisite for hypoxia-induced up-regulation of VEGF and stimulation of 
angiogenesis in vivo (Behzadian MA 1998).
There is currently a growing interest in the use of Anti-VEGF agents in 
treatment of ARMD and diabetic retinopathy with encouraging reported 
successful outcomes.
Pegaptanib is a 28-nucleotide RNA aptamer specific for the VEGF 165 
isoform and binds to it in the extracellular space, leaving other isoforms 
unaffected. This action inhibits such key VEGF actions as promotion of 
endothelial cell proliferation and survival, and vascular permeability (NG 
EW 2006). Intravitreal injection of Pegaptanib has been shown to be 
effective in treatment of choroidal neovascular membrane in age related 
macular degeneration (Gragoudas ES 2004) and in treatment of diabetic 
macular oedema (Cunningham ET Jr 2005) and its safety has been 
evaluated with favourable results in a two year follow up study (D’Amico 
DJ 2006).
Bevacizumab is another anti-VEGF antibody which was was granted 
approval by the FDA in February 2004 for use as first-line therapy in 
metastatic colorectal cancer in combination with fluorouracil-based
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chemotherapy. Bevacizumab binds to all biologically active isoforms of 
VEGF (Gordon MS 2001). It will therefore inhibit all biologic properties of 
VEGF including endothelial cell mitogenic activity, vascular permeability- 
enhancing activity, and those that promote angiogenesis (Fernando NH
2003). Both systemic and intravitral administration of Bevacizumab has 
been shown to be effective in treatment of the neovascular age related 
macular degeneration (Rosenfeld PJ 2005, Michels S 2005).
Ranibizumab is derived from a humanized, monoclonal anti-vascular 
endothelial growth factor antibody and like bevacizumab neutralizes all 
active forms of vascular endothelial growth factor VEGF-A and its 
intravitreal injection has been shown to be effective in treatment of 
neovascular age related macular degeneration (Rosenfeld PJ 2006, Heier 
JS 2006).
Another way how Muller cells may be involved in hypoxia-induced 
pathologic angiogenesis is by release of transforming growth factor beta 
(TGF-p) and basic fibroblast growth factor (bFGF) (Frank RN 1996, 
Behzadian MA 1998). In hypoxia, Muller cells release the active form of 
the TGF-p wheras under normal oxygen tension the latent form is 
released (Behzadian MA 1998). Capillary endothelial cells are capable of 
releasing matrix metaloproteinase-9 (MMP-9) when in direct contact with 
Muller ells or astrocytes or when exposed to TGF-p (Behzadian MA 2001). 
Release of MMPs is associated with generation of leaky vessels as well 
as allowing the endothelial cells to penetrate their underlying basement 
membrane (Liotta LA 1980, Castilla MA 1999). It is believed that the TGF-
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p induced release of MMP-9 is a potential cause of the blood-brain barrier 
breakdown at the onset of the angiogenesis (Behzadian MA 2001).
A further mechanism by which Muller cells may be involved in 
neovascularisation is via the rennin-angiotensin system. Renin is 
expressed in human retina and is specifically localized to the macroglial 
Muller cells. It has been suggested that retinal neovascularization may be 
associated with Muller cell dysfunction (Berka JL 1995).
1.5 Neurotrophins
Neurotrophins (NT) are trophic and mitogenic proteins that play a role in 
the development, differentiation, connectivity and survival of neurones in 
the central and peripheral nervous system, including the retina. NTs are of 
special interest to neurobiologists because they exert their biological 
action primarily on cells of the nervous system. These structurally related 
growth factors have unique activities on target neurones. They all have 
similar biochemical characteristics and are secreted as precursor proteins. 
These proneurotrophins were known to exist for quite some time, but their 
biological activity was only recently discovered (Lee R 2001). The 
biological action of neurotrophins is believed to be regulated by proteolytic 
cleavage, with precursor proteins preferentially activating p75 (see below 
section 1.6) to mediate apoptosis and mature forms activating Trk 
receptors (see below, section 1.6) to promote survival (Lee R 2001). The
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mature part of all neurotrophins shows a high degree of sequence 
similarity.
Four NT have been identified in mammals: nerve growth factor (NGF), 
brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT3), and 
neurotrophin 4, which is also known as neurotrophin 5 (NT4/5). They are 
derived from a common ancestral gene and are similar in sequence and 
structure. NTs are expressed in regions that are invaded by sensory 
axons during development to provide them with trophic support en route to 
their final target (Farinas I 1996, 1998; Huang EJ 1999, RingstedtT 1999). 
Many neurons have an autocrine role expressing BDNF (Mannion RJ 
1999, Brady R 1999).
There are other growth factors, only briefly mentioned here, with 
neutotrophic effect. These factors are not part of the neurotrophins family 
because they are not derived from the same ancestoral gene and include 
ciliary neurotrophic factors (CNTF) and basic fibroblastic growth factor 
(bFGF). CNTF has the biological effect on differentiation of photoreceptor 
cells and promoting the survival and axonal growth of ganglion cells 
(Whahlin KJ 2000, Chong NH 1999, Mey J 1993). In addition to affecting 
the differentiation of retinal neurons, CNTF also promotes Muller glia 
genesis in the postnatal mouse retina (Goureau O 2004).
NGF was the first NT described in 1950s by Rita Levi-Montalcini who was 
subsequently awarded the Noble prize in physiology and medicine in 1986 
for this discovery. NGF was purified as a factor capable of supporting the 
survival of sympathetic and sensory spinal neurons in culture (Levi- 
Montalcini R 1987). It has been shown that NGF is synthesised and
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secreted by cells of sympathetic and sensory target organs (Korsching S 
1993 review). It is then captured by receptor-mediated endocytosis in 
nerve terminals and is transported through axons to neuronal cell bodies 
where it acts to promote neuronal survival and differentiation. There are 
other sources of NTs synthesis. Following peripheral nerve injury, 
macrophages infiltrate the nerve and release cytokines, which induce the 
synthesis of NGF in Schwann cells and fibroblasts within the injured nerve 
(Korsching S 1993 review). NGF synthesised in the damaged nerve is 
believed to be essential for survival and regeneration of injured neurons. 
BDNF in its mature form is 52% identical to NGF at the amino acid level 
(Leibrock J 1989). Cells known to express BDNF include fibroblasts 
(Cartwright M 1994), astrocytes (Moretto G 1994), neurons (Barakat- 
Walter I 1996), megakarayocytes/platelets (Yamamoto H 1990) and retinal 
Muller cells (Oku H 2002). During development, BDNF has been 
implicated in neuronal differentiation, maturation, survival and synapse 
formation (Henderson CE 1996) whereas in the adult one of its most 
important roles is neuroprotection after injury (kishino A 1997, Mansour- 
Robaey S 1994).
BDNF mRNA levels are known to be up regulated in response to ganglion 
cell axonal injury in rats. This observation suggests that endogenous 
BDNF may contribute to a natural neuroprotective process after optic 
nerve injury. To achieve this, target cells in the retina need to be 
expressing the appropriate receptor in the right isoform and at adequate 
levels (see section 1.6). BDNF may aid recovery of the detached retina
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after reattachment (Lewis GP 1999) and ganglion cell regeneration 
following optic nerve injury (Mansour-Robaey S 1994).
The third membrane of the neurotrophin family to be discovered was NT3 
(Ernfors P 1990). NT3 promotes the differentiation and supports the 
survival of neuroblasts derived from the neural crest in early development 
(Zhou XF 1998). The differentiation and survival of a subpopulation of 
large sensory neurons after their axons arrive at their targets is also 
dependent on presence of NT3 (Zhou XF 1998) and sympathetic neurons 
require NT3 for survival in the late developmental period (Tafreshi AP
1998). NT3 binds to all Trk receptors and some of its biological effects can 
occur through binding to Trks other than TrkC, which is its specific 
receptor. For instance the sympathetic neurons of the superior cervical 
ganglion require both NT3 and NGF for survival (Glebova NO 2005).
NT4 is the most recently discovered NT in mammals (Hallbook F 1991, IP 
NY 1992) and its biological role is not fully understood. NT4 has not been 
detected in avian species. All NT knockout mice have proven lethal during 
early postnatal development apart from NT4 deficient mice that only show 
minor cellular deficits and develop normally to adulthood. NT4 knockout 
mice have recently been reported to require NT3 in early postnatal 
development and NT4 later in mature animals for survival of sensory 
neurons. NT-4 infusion into the visual cortex alters responses and blocks 
the effect of monocular deprivation in cat during the critical period 
(Gillespie DC 2000). Even after responses to the deprived eye are 
adversely affected, NT-4 infusion is able to restore them (Gillespie DC
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2000). These findings suggest that activation of NT-4 receptors during the 
critical period promotes connectivity independent of correlated activity.
All the NTs are synthesized as precursor proteins with an approximate 
molecular weight of 30 kDa. They are later cleaved to form the mature 
form and are all capable of forming noncovalent-linked homodimers with 
each other. Each monomer is approximately 13 kDa (reviewed by Huang 
EJ and Reichardt LF 2001).
The structures of NGF, NT-3, and NT-4 and of NT-3/BDNF and NT- 
4/BDNF dimers have been defined. A feature of their structures (a tertiary 
fold and cystine knot) is also present in several other growth factors, 
including platelet-derived growth factor (PDGF) and transforming growth 
factor ft  (TG F-f') (McDonald NQ 1991, Fandl JP 1994, Robinson RC 
1995, 1999, Butte MJ 1998; reviewed in McDonald NQ & Chao MV 1995). 
In human retina the exact cellular source of NT production and their 
receptors has not been described. In other mammals, NT production has 
been identified in retinal ganglion cells, amacrine cells and Muller cells 
(Garcia M 2003, Avwenagha O 2006).
The first suggestion of the clinical use of neurotrophins was in 1980s 
based on the observation that the basal forebrain cholinergic neurons are 
consistently affected at an early stage of Alzheimer's disease (Hefti F and 
Weiner WJ 1986). It has been shown that NGF is capable of preventing 
the degeneration of cholinergic neurons in adult rats with experimental 
lesions mimicking the cholinergic deficit in Alzheimer's (Hefti F and 
Weiner WJ 1986). Fisher et al have shown that in adult rats a continuous 
intraventicular infusion of NGF over a period of four weeks can partly
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reverse the cholinergic cell body atrophy and improve retention of a 
spatial memory task in behaviourally impaired animals (Fischer W 1987). 
Several clinical trails have been conducted aiming to treat 
neurodegenerative disorders in which specific group of neurons are 
affected, as in amyotrophic lateral sclerosis, diabetic neuropathy, 
Altzheimer’s and Huntington diseases, with disappointing outcomes 
(reviewed in Thoenen H & Sendtner M 2002). It remains to be seen if 
use of NTs in human retinal disorders has any beneficial effect.
1.6 Neurotrophin receptors
NTs exert their biological effects via two different classes of receptors. The 
low affinity receptor p75 bind all members of NTs. This receptor belongs to 
the tumour necrosis factor (TNF) receptor superfamily (Chao MV 1994, 
Bothwell M 1995). The cytoplasmic domain of this receptor contains a 
"death" domain structurally similar to those in other members of this 
receptor family (Liepinsch E 1997). p75 transmits signals important for 
determining appropriate apoptosis of neonatal neurons not reaching their 
proper targets (Nykjaer A 2005). During normal development nerve growth 
factor seems to be able to activate this low affinity receptor causing the 
death of neurons that lack TrkA (Dechant G 1997). Nerve growth factor 
can therefore prevent apoptosis through its specific receptor, trkA, but 
promote programmed cell death by signalling through p75 receptor 
(Dechant G 1997).
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The high affinity receptors however belong to the thyrosine kinase 
receptor family. NGF binds to tropomysin-related kinase A (TrkA), BDNF 
and NT4 both bind to TrkB and NT3 bind to TrkC.
NT binding to high affinity receptors leads to receptor dimerisation and 
subsequently activation of the thyrosine kinase present in their 
cytoplasmic domains. Phosphorylation of the intracellular catalytic domain 
will in turn initiate a phosphorylation cascade and cell growth or survival.
Neurotrophin Specific Receptor Human chromosome 
location
NGF TrkA 1
BDNF TrkB 11
NT3 TrkC 12
NT4/5 TrkB 19
Table 1.3 Chromosomal localisation of genes encoding for neurotrophins and 
their receptors.
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Figure 1.3 Diagramatic presentations of neurotrophic factors and their 
receptors.
NGF= Nerve growth factor, BDNF= brain derived neurotrophic factor,
NT3= neurotrophin 3, NT4/5= neurotrophin 4/5, TrkA= thyrosine kinase A, 
TrkB= thyrosine kinase B, TrkC= thyrosine kinase C, p75=low affinity 
neurothrophin receptor
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Binding of NTs to these truncated receptors (reviewed in Reichardt LF 
and Farinas I 1997) does not cause activation of the intracellular pathway, 
for which they may function as dominant negative isoforms. Both full 
length and truncated form of TrkB and TrkC receptors have been detected 
in neurons while only truncated TrkB and TrkC isoforms have been 
detected in nonneuronal cells (Valenzuela D 1993, Tsoulfas P 1993, Klein 
R 1990, Middlemas DS 1991, Martin-Zanca D 1990). The functions of 
truncated isoforms of TrkB and TrkC in nonneuronal cells may include 
presentation of neurotrophins to neurons. Within neurons, truncated 
receptors are likely to inhibit productive dimerisation and activation of full- 
length receptors, thereby attenuating responses to neurotrophins (Eide FF 
1996). Selective binding and internalisation of BDNF by t-TrkB has been 
reported suggesting that a function of this receptor might be to restrict 
BDNF availability. This may allow several BDNF sensitive systems to 
develop independently even though they are separated by only short 
distances (Biffo S 1995).
The distribution of TrKA and TrkB was first described in the ganglion cell 
layer, Muller cells, and optic axons of rat retina (Jelsma TN 1993, 
Zanellato A 1993). These receptors have also been reported to 
immunolocalise in all retinal cell layers in rat except the photoreceptor 
layer and optic nerve (Rickman DW 1995).
Expression of mRNA for all high affinity receptors has been detected in 
the neuroblastic inner nuclear and ganglion cell layers of embryo, newborn 
and adult rat retinas (Ernfors P 1992, Jelsma TN 1993). In chicks, TrkC
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mRNA has been identified in all cell nuclear layers but predominates in the 
ganglion cell and inner nuclear layers (Bovolenta P 1996, Hallbook F 
1996). In mammals the low affinity receptor, p75, has been found in Muller 
cells and retinal ganglion cells (Garcia M 2003, Schatteman GC 1988).
The expression of specific receptors for BDNF and NT4 by photoreceptor 
cells in mammals has not been demonstrated as yet and it is believed that 
protection of photoreceptors by neurotrophic factors occurs indirectly 
through activation of other cells (Wahlin KJ 2000). In their study Wahlin et 
al demonstrated that intravitreal injection of BDNF, CNTF and fibroblast 
growth factor (FGF2) in mice resulted in activation of intracellular 
signalling pathways in Muller cells, amacrine and ganglion cells. The same 
effect in signalling pathways was not demonstrated in the photoreceptor 
cells supporting the hypothesis that the effect of neurotrophic factors on 
the photoreceptors may be indirect through activation of Muller cells and 
other retinal cells (Wahlin KJ 2000).
In experimental studies in the rat, central nervous system injuries to the 
spinal cord or the brain are followed by down-regulation of neuronal Trk 
receptors (Kobayashi NR 1997, Liebl DJ 2001, Venero JL 1994). BDNF 
mRNA levels, however, are transiently up regulated after optic nerve crush 
(Gao H 1997) although this does not prevent or delay retinal ganglion cell 
death. The effect of BDNF injection or gene delivery to the retina is 
therefore expected to be short lived or even absent, as indeed is the case 
(Mansour-Robaey S 1994, Clarke DB 1998, Di Polo A 1998).
Cheng et al (Cheng L 2002) have demonstrated down-regulation of TrkB 
mRNA following optic nerve injury in rats and have further shown that
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TrKB gene delivery in combination with exogenous BDNF extends the 
survival of retinal ganglion cells after injury.
1.7 Mechanism of intracellular message transmission
Ligand binding of TrkB receptors is known to result in phosphorylation of 
cytoplasmic tyrosine kinase residues on the cytoplasmic domain of these 
receptors. This autophosphrylation is then followed by downstream signal 
transduction of molecules such as mitogen activated protein kinase 
(MAPK) and cAMP responsive element binding protein (CREB) (Weng G 
1999, Segal RA 1996, Meyer-Franke A 1995). The immediate early genes 
c-fos and c-jun are also rapidly upregulated in the activated cells (Sheng 
M 1990).
Recent reports studying the response produced via TrkB receptor after 
NT’s binding suggest that BDNF and NT4 at very low concentrations 
(thousand-fold lower concentration than glutamate) are capable of 
depolarization of neurons in the central nervous system as rapidly as 
glutamate (Kafitz KW 1999). The same study reported that NT3 was found 
to produce much smaller response and NGF was ineffective.
It has been shown that in the rabbit retina BDNF can, within minutes, 
increases the release of dopamine from amacrine cells by activating TrkB 
receptors. The intracellular mechanism of TrkB receptor activation 
involves activation of phospholipase-Cgamma, with the subsequent 
production of inositol (1,4,5) trisphosphate (IP-3) and calcium release from 
the endoplasmic reticulum. This calcium release seems to be the actual 
trigger for BDNF-induced release of dopamine (Neal M 2003).
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Studies using primarily PC12 cells have identified the key factors in the 
signalling pathways following binding of neurotrophins to TrK receptors. 
Based on studies involving Trk A receptor and NGF the following general 
scheme of intracellular signalling has been proposed (Kaplan D R & 
Stephens R M 1994). Binding of NGF to TrkA activates its tyrosine kinase 
activity, leading to phosphorylation on specific tyrosine residues within the 
intracellular domains of the receptor20. These phosphotyrosyl residues act 
as docking sites for other signaling molecules, including phospholipase C- 
v (PLC-v) and She (Segal RA & Greenberg ME 1996, Kaplan D R & Miller 
FD 2000). Active PLC-v cleaves phosphatidylinositol 4,5-biphosphate 
(PI(4,5)P2) to generate both IP3, and diacylglycerol. Additionally, tyrosine 
phosphorylation of She triggers Shc/Grb2/Sos interaction, Ras activation  
and a series of phosphorylation reactions including Raf, MEK and 
m itogen associated protein kinase (MAP kinase). She can also 
activate  phosphoinositide 3 -k inase  (P I3  kinase) via protein- 
protein interaction involving Ras and Gab-1. PI3 kinase phosphorylates 
the phosphatidylinositol lipids to produce PI(3,4)P2 and PI(3,4,5)P3 (Toker 
A & Cantley LC 1997). In summary, binding of NGF to TrkA may activate 
at least three main signaling pathways in PC12 cells: PLC-v, MAP kinase 
and PI3 kinase (Figure 1.4).
53
®0
, V!c V-
c H
o
\  S H c f o r b - I Sos
Gab-1
PI-3K
PLC-
gamma
Synaptic
transmission
Survival 
Axonal growth
\ Raf^
MEK-1/2 
(PKB ) x
" VtAPK-li 2
i
Survival
Axonal growth 
Survival
Figure 1.4 Intracellular signalling pathways associated with NT binding to 
Trk receptors. (Adapted from Thoenen H & Sendtner M 2002)
NT= Neurotrophins, Trk=Tyrosine kinase receptor, PLC-gamma= 
phospholipase C-gamma, IP3=inositol (1,4,5) trisphosphate, SHC= 
A transform ing protein, Grb-2=Growth factor receptor bound 
protein 2, Sos= Son of sevenless protein, Gab-1 = Grb-2- 
associated protein 1, PI-3K= phosphatidylinositol-3 kinase, PKB= 
Protein kinase B also known as AKT, RAS= RAS is a plasma 
membrane associated guanine nucleotide binding protein, Raf= 
Raf is a serine/threonine kinase normally positioned downstream 
of Ras in numerous signal transduction pathways, M APK-l/2= 
Mitogen activated protein kinase, M E K -l/2=  MAPK kinase.
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1.8 Role of Muller cells in neuronal protection
Neuronal cell death in the retina is of special interest to investigators not 
only because of its biological importance in various disorders, but also 
because retinal apoptosis can be regarded as a model system for cell 
death in the central nervous system. There are a number of 
neurodegenerative retinal diseases in which apoptosis is believed to be 
the major pathogenic mechanism. These include photoreceptor 
degeneration in retinitis pigmentosa and age related macular 
degeneration, retinal ganglion cell death in glaucoma and other optic 
neuropathies, and panretinal diseases such in diabetic retinopathy. 
Neurotrophic factors have been shown to inhibit photoreceptor and 
ganglion cell apoptosis, both in vitro and in vivo (Steinberg RH 1994, 
LaVail MM 1998) but it is still unclear as how NTs protect photoreceptor 
cells from degeneration. Furthermore the expression of TrkB (specific 
receptors for BDNF) by photoreceptors in mammals has not been 
demonstrated as yet. It has therefore been proposed that NTs effect may 
be indirect via the supporting cells of the retina.
Muller cells, as the main glial element of the retina, express receptors for 
most of the molecules that have been shown to rescue photoreceptors. 
They also express glial fibrillary acidic protein (GFAP) in response to a 
number of stimuli including retinal degeneration (Ekstrom P 1988). It has 
been shown that loss of Muller cells can lead to photoreceptor death 
(Dubois-Dauphin M 2000). Whalin et al have shown that intraocular 
administration of BDNF can lead to activation of Muller cells and not 
photoreceptors (Wahlin KJ 2000).
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The mechanism by which Muller cells can protect photoreceptors is 
however unclear and all the evidence is indirect. Release of a secondary 
factor by glial cells or a cell contact-mediated mechanism is a possible 
method of protection provided by these cells. Harada T et al (2000) have 
shown that basic fibroblast growth factor (FGF2), which is photoreceptive 
protector, is released at higher levels by Muller cells in response to 
exogenous NT3. They have also demonstrated that the reverse is true 
when NGF is administered causing a decrease in FGF2 production as a 
result. There is therefore a fine balance between pro and anti apoptotic 
effect that can be initiated by Muller cells in response to exogenous 
neurotrophic factors.
The low affinity NT receptor, p75, is expressed in human Muller cells 
(Garcia M 2003) and its expression is up regulated in diabetes (Hammes 
HP 1995). Ischemia and reperfusion in rats’ retina is also associated with 
up-regulation of p75 (Tomita H 1998, Vecino E 1998) suggesting an 
enhanced role by Muller cells in response to available neurotrophins and 
therefore increased neuroprotective effect (Vecino E 1998).
1.9 Neurotrophins in retinal laser injury
Laser photocoagulation is an established treatment for a number of retinal 
neovascular diseases, however the mechanism of its action is not yet fully 
understood. Retinal photocoagulation causes outer retinal necrosis, 
hyperplasia of the RPE and glial cell proliferation and migration, eventually 
leading to localized fibrous scar formation (van der Zypen E 1986, 
Marshall J and Bird A 1979, Tobe T 1995). Cellular activation may be 
reflected in changes of expression of various markers such as glial
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fibrillary acidic protein (GFAP), which is highly expressed by astrocytes 
but minimally expressed by resting Muller cells, which increase their 
expression of GFAP when activated (Humphery MF 1997). Similarly, RPE 
cells, which do not normally stain for CD68 in vivo, express this molecule 
under culture conditions as evidence of activation (Limb GA 1997).Up- 
regulation of cell marker expression has become an important marker of 
injury in central nervous system tissues including the retina (Humphrey 
MF 1997, Lewis GP 1989), where GFAP up regulation in Muller cells 
occurs rapidly after retinal detachment (Erickson PA 1987) as well as 
following laser photocoagulation (Humphrey MF 1993 and 1997). The 
cellular and molecular events induced by retinal photocoagulation and the 
subsequent wound healing responses are complex and as yet 
incompletely characterized processes. Experimental models suggest that 
these events are regulated by a variety of growth factors (Xiao M 1999). 
Changes in pattern of staining for NT4, GFAP and CD68 have been 
reported following laser photocoagulation in the human retina (Ghazi- 
Nouri S 2003).
1.10 Investigation of the neuroprotective role of Muller glia in the retina
There is sufficient evidence that glial cells play a central role in the in the 
nervous system through their release of neurotrophins, as that illustrated 
by Muller glia in the retina. Although several studies have examined the 
role of Muller glia in different animal species, there is only one published 
report investigating the mRNA expression of NGF, BDNF and NT3 and 
their specific receptors by cultured human Muller cells (Oku H 2002). This
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study did not investigate the mRNA expression of NT4 and did not 
examine their protein expression by Western blot analysis.
To investigate the role of these molecules in the pathogenesis of retinal 
degenerative disease, it is therefore of interest to investigate the 
expression of these growth factors as well as their receptors in vitro at 
mRNA and protein level using cultured human Muller cells. It is also of 
particular importance to study whether changes in expression of 
neurotrophins and their receptors in vivo may be observed in conditions 
such as PVR and laser induced retinal injury. This would provide better 
understanding of the role of Muller cells and neurotrophins in retinal 
neuroprotection. To investigate the expression of these molecules, a 
series of laboratory experiments and clinical studies were designed with 
the following aims:
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Aims
The aims of the work in this thesis were to:
o Characterise the expression of BDNF and NT4 and their 
common receptor, TrkB, by cultured human Muller cells at 
mRNA and protein levels, 
o Define the expression of BDNF, NT4 and TrkB in normal 
human retina.
o Investigate the changes in expression of BDNF, NT4 and 
TrkB in retinectomy sections of patients with PVR. 
o Determine the changes in expression of BDNF, NT4 and 
GFAP in melanoma affected human retina following laser 
photocoagulation.
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Chapter 2 
Materials and Methods
2.1 Cell line and culture conditions
MIO-M1: Moorfields, Institute of Ophthalmology-Muller 1 cell line
(Human Muller cell line).
MIO-M1 cells were grown in Dulbecco's modified Eagle's medium (DMEM) 
(Sigma, St. Lois, MO) containing glutamax-1, sodium pyruvate, 4500mg/l 
glucose and pyridoxine. All media were supplemented with 10% foetal calf 
serum (FCS), penicillin (42U/ml), streptomycin (42 U/ml) and incubated at 
37°C with 5% CO2. Cells were kept sub-confluent and passaged every 3-4 
days. For passage, they were washed twice in phosphate buffered saline 
(PBS) before being harvested using Trypsin-EDTA and then washed in 
DMEM and re-plated. Subcultures 20 to 30 were used in the experiments.
2.2 Cell culture with PDGF supplement
Cells were incubated under conditions in section 2.1 for 24, 48 and 72 
hours. Platelet derived growth factor (PDGF) (Sigma, St. Lois, MO) in a 
total concentration of 50 ng/ml (Haber M 2003, Price RL 2003, Zheng Y 
2003) was added to culture medium and RNA was isolated 24 hours later 
to assess the effect of PDGF on mRNA expression in these cells.
2.3 Cell culture with NT4 supplement
To assess the effect of NT4 on mRNA expression of t-TrkB MIO-M1 cells 
were cultured as above and recombinant human NT4 (R&D Systems, 
Mineapolis, MN, USA) was added at concentrations of 1 ng/ml, 10ng/ml, or 
50ng/ml to the culture medium every day for 5 days prior to RNA 
extraction for RT-PCR.
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2.4 Preparation of cell lysates for Western blotting
Cell lysates were prepared using sub-confluent cultures. Medium was 
removed and cells were washed twice in PBS. Cells were harvested using 
Trypsin-EDTA, washed in medium and spun for 5 minutes to form a pellet. 
This was washed in PBS and lysed with 200ul cold radioimmune 
precipitation assay buffer (RIPA buffer: 1% Nonidet P-40, 0.5%  
deoxycholic acid, 0.1% SDS, 158 mM NaCI, and 50 mM Tris [pH 7.2]). 
Samples were stored at -80°C until use.
2.5 Western blot
Expression of BDNF, NT4 and TrkB proteins by cultured MIO-M1 cells 
was assessed using Western blot analysis. Aliquots of Muller cell lysates 
(1.5 mg/mL, measured using spectrophotometer, Eppendorf 
BioPhotometer, Hamburg, Germany) were resolved on 7% Tris-acetate 
polyacrylamide gels (NuPAGE; Invitrogen, Groningen, The Netherlands) 
for 50 minutes at 2000 V in Tris-acetate running buffer (50 mM Tris, 50 
mM tricine, and 0.1% SDS [pH 8.3]; Invitrogen, Paisley, UK). Molecular 
weight marker (Santa Cruz, Ca, USA) was used as internal standards. 
Proteins were then transferred to nitrocellulose membranes for 60 minutes 
at 30 V followed by incubation in 2% blocking reagent (in TBS, pH 7.4) for 
2 hours at room temperature. Membranes were then incubated with 
primary rabbit polyclonal antibody (Santa-Cruz, 1 in 200 dilution) 
overnight. Membranes were washed in Tween TBS 0.1% twice and 
incubated with HRP conjugated goat anti-rabbit IgG (Santa Cruz) for 90 
minutes (1 in 1500 dilution).
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Immunocomplexes were detected by enhanced chemiluminescence (ECL; 
Amersham, Amersham, UK). Images were analyzed and processed using 
an image reader (LAS-1000 Pro, ver. 2.1; Fuji, Bedford, UK).
Mouse brain extract (Santa Cruz, Ca, USA) was used as positive control 
for BDNF and NT4 antibodies.
2.6 Antibodies and dilutions used for Western blotting
All antibodies were supplied by Santa Cruz (Santa Cruz, Ca, USA) and 
were polyclonal rabbit antibodies. Dilutions used were 1:200 in each case 
(Table 2.1) as recommended by the supplier.
Primary antibodies species dilution
Anti BDNF (Santa-Cruz) rabbit polyclonal 1:200
Anti NT4 (Santa-Cruz) rabbit polyclonal 1:200
Anti TrkB (Santa-Cruz) rabbit polyclonal 1:200
Anti t-TrkB (Santa-Cruz) rabbit polyclonal 1:200
Table 2.1 Antibodies and dilutions used for Western blotting
2.7 RNA extraction
Muller cells were cultured as described above. An RNA isolation kit 
(RNeasy, Qiagen, West Sussex, UK) was used for RNA extraction 
according to the protocol. Cells were trypsinised followed by addition of 
DMEM plus 10% FCS medium to inactivate the trypsin. Cells were 
subsequently centrifuged at 300 x g for 5 minutes and the supernatant 
was completely aspirated. The pellet obtained was re-suspended in the
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lysis buffer containing guanidine isothiocynate (GITC) and li- 
Mercaptoethanol (ft-ME) followed by passing the lysate at least 5 times 
through a 20-gauge needle fitted to an RNase-free syringe. Ethanol (70%) 
was then added to the sample and it was applied to an RNeasy mini 
column for RNA to bind to the membrane and contaminants were washed 
away. The bound RNA was eluted in 30pl of water and the RNA 
concentration was quantified using Eppendorf Biophotometer (Eppendorf, 
Hamburg, Germany) prior to storing at -  80°C till use.
2.8 RT-PCR
cDNA samples were prepared by using mRNA transcription Promega 
Reverse Transcriptase System (Promega, Southampton, UK). Gene 
specific primers were used as shown in Table 2.2.
For each PCR, cDNA corresponding to 0.1 ug RNA was amplified in a 
reaction tube of total volume 100ul containing 200uM dNTPs, 2mM MgC^ 
(with contribution from first-strand cDNA reaction), 10mM Tris-HCI, 50mM 
KCI, 0.1% Triton X-100, 1 ul of each upstream or downstream primer and 
2.5 unit of Taq DNA polymerase. A reaction tube containing GAPDH 
primers was used as internal control for the PCR reactions. Two negative 
controls were included; one including all PCR reaction components except 
primers and another one with 0.1 ug RNA instead of cDNA to ensure the 
absence of residual DNA contamination. GAPDH primers were used in 
this negative control reaction tube. PCR cycles consisted of an initial 2 
minute denaturation step at 94°C followed by 35 cycles of 94°C for 30 
seconds, 60°C for 1 minute, 68°C for 2 minutes, and a final extension at
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68°C for 7 minutes in an automated thermal cycler (Mastercycler gradient, 
Eppendorf, UK).
2.9 PCR primers
Gene specific primers were used for RT-PCR experiments to amplify 
BDNF, NT4, TrkB, t-TrkB and GAPDH. The primer used for TrkB 
amplification was specific for the kinetic domain of the receptor, 
recognising the full-length receptor. The full sequence of the gene for 
these factors is in the appendix.
Gene Size
(bp)
Upstream sequence (5'- 
3')
Downstream sequence (5'- 
3')
BDNF 222 AAC AAT AAG GAC GCA GAC TT TGC AGT CTT TTT GTC TGC CG
NT4 202 AGC GAA ACT GCA CCA GCG 
AG
CAC CTT CCT CAG CGT TAT CA
TrkB
(kin)
571 AGG GCA ACC CGC CCA CGG 
AA
GGA TCG GTC TGG GGA AAA GG
t-TrkB 161 TAA AAC CGG TCG GGA ACA 
TC
ACC CAT CCA GTG GGA TCT TA
GAPDH 600 CCA CCC ATG GCA AAT TCC 
ATG GCA
TCT AGA CGG CAG GTC AGG 
TCC ACC
Table 2.2 Gene specific primers used in RT-PCR to detect BDNF, NT4, TrkB 
kinetic domain for the full-length receptor, t-TrkB and GAPDH.
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2.10 Horizontal agarose gel electrophoresis
Amplified cDNA samples were resolved in 1% agarose gel containing 2 pi 
ethidium bromide (10mg/ml stock solution) per 100 ml gel. The gel was 
immersed in 1X TAE buffer and 100V was applied for approximately 1 
hour. A 100bp DNA ladder (New England Biolabs, Ipswich, MA, USA) was 
used as marker and 6X loading dye (Fermantas, Ontario, Canada) added 
to each sample prior to loading into the gel.
2.11 Preparation of cells for immunocytochemistry
Muller cells were cultured for 48 hours on fibronectin-coated (5 pg/mL) 
glass chamber slides (NalgeNunc, Inc., Roskilde, Denmark), fixed in 4%  
paraformaldehyde (PFA) in phosphate-buffered saline (PBS; pH 7.2) for 
10 minutes, and incubated for 1 hour with primary antibodies (see 
antibodies and dilutions as listed in table 2.1) diluted in 0.5% blocking 
reagent (Roche Molecular Biochemicals, Lewes, UK) in Tris-buffered 
saline (TBS; pH 7.5).
For negative controls, rabbit IgG isotypes (DAKO, Glostrup, Denmark) 
matching those of the test antibodies were used at the same 
concentrations as above. A second negative control contained 1X TBS 
instead of the primary antibody. After incubation with primary antibody, 
specimens were washed in TBS, followed by incubation for 45 minutes 
with goat anti-rabbit antibodies conjugated with FITC (Alexa Fluor 546, see 
table 2.3) (Invitrogen, Paisley, UK). Specimens were then washed and 
mounted on glass slides (Vectashield mounting medium; Vector 
Laboratories, Burlingame, CA). Fluorescent images were recorded using a 
confocal scanning laser microscope (BioRad Radiance 2000 AGR-3 (Q)).
66
2.12 Tissue preparation for immunohistochemistry
Human retinal tissues were fixed in 4% paraformaldehyde (4%PFA) and 
kept at 4° C until use. PVR retinectomy specimens were fixed immediately 
in operating theatre. The cadaveric donor tissues were fixed within 24 to 
48 hours from harvesting. The PFA was replaced with fresh solutions once 
a month. Embedding medium consisted of 5g agarose type XI of low 
gelling temperature (Sigma A3038) and 1g sodium azide in distilled water 
in a total volume of 100ml. This mixture was heated at approximately 50° 
C.
Specimens were washed in 1X PBS buffer prior to being inserted and 
orientated in the agarose solution. The gel was allowed to cool and solidify 
and stored within a humidity box at 4°C till ready for sectioning.
Vibratome series 1000 (Agar Scientific, Essex, UK) was used for 
sectioning the specimens with low speed, the amplitude set on 5 and the 
thickness on 100 microns. Sections were stored in 4% PFA prior to 
staining.
For immunostaining specimens were placed in Multidish wells 
(NalgeNunc, Inc., Roskilde, Denmark) free floating in 500 pi 1XPBS for 14 
hour and then incubated with primary antibodies (see table for details and 
dilution) at 4°C on a shaker overnight. After a further period of 14 hour 
wash in 1XPBS, secondary antibodies (see table for details and dilutions) 
were added to the wells and incubated again overnight 4°C on a shaker. 
To-Pro3-lodide (1:5000 dilutions) was used for 1 hour for nuclear staining. 
Specimens were washed as above prior and after nuclear staining.
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Rabbit IgG (DAKO, Golstrup, Denmark) and Mouse IgG (Sigma, St. Lois, 
MO, USA) were used at the same concentration as the primary antibodies 
for negative controls. A second negative control was also prepared without 
addition of primary antibodies.
Specimens were then washed and mounted on glass slides (Vectashield 
mounting medium; Vector Laboratories, Peterborough, UK). Fluorescent 
images were recorded using a scanning laser confocal microscope 
(BioRad radiance 2000 AGR-3 (Q)).
Primary antibodies Species Dilution
Anti BDNF (Santa-Cruz) rabbit polyclonal 1:200
Anti NT4 (Santa-Cruz) rabbit polyclonal 1:200
Anti TrkB (Santa-Cruz) rabbit polyclonal 1:200
Anti t-TrkB (Santa-Cruz) rabbit polyclonal 1:200
Anti-Rhodopsin (Rho4D2)
(gift from Bob Molday, Canada)
mouse monoclonal 1:40
GFAP (Santa-Cruz) mouse monoclonal 1:200
Secondary antibodies Species Dilution
Anti-rabbit (Alexa Fluor 546) goat 1:500
Anti-mouse (Santa-Cruz) donkey 1:250
Anti-mouse (Alexa Fluor 488) donkey 1:500
Table 2.3 Primary and secondary antibodies used in double-labeling of cells 
and retinal tissues.
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2.13 Confocal laser scanning microscopy of fixed Muller cells and retinal 
tissues
A BioRad Radiance 2000 AGR-3 (Q) laser scanning confocal microscope 
was used for imaging of stained Muller cells and retinal tissues. A series of 
images through the thickness of the specimens were obtained and stored 
for image analysis. Images were analysed by three different observers 
and there was complete agreement in their findings during image analysis.
2.14 Laser induced injury in patients
2.14.1 Patients and methods
Laser photocoagulation was performed on the retinas of 4 patients (2 
males and 2 females, median age 70 years) prior to undergoing 
enucleation for malignant melanoma of the choroid (Table 2.4). The study 
was performed in accordance with the ethical standards laid down in the 
1964 Declaration of Helsinki and approved by Moorfields Eye Hospital 
Research Ethics Committee.
Patients with pre-existing retinal disease or clinically significant retinal 
detachment associated with the choroidal melanoma were excluded from 
the study. All four patients received three rows of 10 - 15 creamy white 
argon green laser burns away from the choroidal melanoma. Laser 
photocoagulation was performed 1 day prior to enucleation in one patient, 
2 days prior to enucleation in one patient and 6 days prior to enucleation 
in 2 patients. Laser spots were 500 micron and of 0.1 second duration. 
Other laser treatment details are summarized in table I. Eyes were fixed in
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4% paraformaldehyde in 0.1 M phosphate buffer (pH = 7.4) immediately 
after enucleation.
2.14.2 Immunohistochemical staining of lasered retina
Retinal tissue containing the laser foci were paraffin embedded and 
sections of 7pm thickness prepared for immunohistochemistry. Retinal 
sections from three non-lasered eyes with malignant choroidal melanoma 
and three normal eyes from corneal donors with normal retina were used 
as controls. Slides were immersed in pepsin solution (0.4 gms in 100 mis 
of 0.1 N HCL) at 37°C for 15 minutes, washed twice in tris buffered saline 
(TBS) and placed in 0.5% blocking reagent (Roche Molecular 
Biochemicals, Lewes, UK) in TBS for 20 min. Sections were incubated 
overnight at room temperature with a panel of primary monoclonal 
antibodies diluted in 0.5% blocking reagent in TBS as follows: Anti- BDNF 
(MAB248, 10ug/ml- R&D Systems, UK); anti-NT3 (MAB267, 5ug/ml- R&D 
Systems, Mineapolis, MN, USA); anti-NT4 (MAB268, 5ug/ml- R&D 
Systems, Mineapolis, MN, USA); anti-GFAP (Clone 6F2- 10 ug/ml- Dako, 
Glostrup, Denmark) and anti-CD68 (Clone PG-M1 10ug/ml- Dako, 
Glostrop, Denmark). Mouse IgG isotypes matching those of the test 
antibodies (Sigma, St. Lois, MO, USA) were used as negative controls in 
the assay. Following incubation with primary antibody, specimens were 
washed and further incubated for 30 min with 50 pi of biotin-labelled rabbit 
anti-mouse antibody (Dako, Glostrup, Denmark). After washing in TBS, 
slides were then covered with 50 pi Strept/Avidin/AP complex (Dako, 
Glostrup, Denmark) and incubated for 45 minutes, washed twice with TBS 
and further incubated for 30 min with 50 pi of alkaline phosphate substrate
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(Vector Red- Vector Laboratories, Peterborough, UK). Slides were 
counterstained with Mayer’s haematoxylin prior to microscopy analysis. 
Selected non-immunolabelled sections were also stained with 
haematoxylin and eosin to permit evaluation of the overall morphology of 
the sections. Slides were analysed by three different observers under light 
microscopy and there was complete agreement in their findings during 
slide analysis.
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Origin of retinal specimen 
(age, gender)
Location of laser burns 
(spot energy)
Laser prior to 
enucleation (days)
Melanoma 
(70, M)
Nasal (400-700mW) 1
Melanoma 
(82,F)
Superior (410-650mW) 2
Melanoma
(70,F)
Inferior (30-60 mW) 6
Melanoma 
(47,M)
Superior (30-60 mW) 6
Melanoma 
(68, M)
No laser n/a
Melanoma 
(70, M)
No laser n/a
Melanoma 
(46, F)
No laser n/a
Cadaveric donor (73, M) No laser n/a
Cadaveric donor (26, M) No laser n/a
Cadaveric donor (66, M) No laser n/a
Table 2.4 Details of specimen used in the laser induced injury study of retinal 
tissues.
All melanoma affected eyes were fixed in 4% paraformaldehyde (PFA) 
immediately after enucleation. The cadaveric donor eyes were fixed in 4% PFA 
within 24 to 48 hours from harvesting.
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Sample Age (years) Gender Condition
1 80 F PVR
2 56 F PVR
3 72 F PVR
4 67 F PVR
5 70 M PVR
6 52 M PVR
7 55 M PVR
8 38 M PVR
9 55 M Cadaveric donor
10 50 M Cadaveric donor
11 75 M Cadaveric donor
Table 2.5 Details of specimens used in the immunohistochemistry study of 
retinal tissues.
The PVR specimens were fixed in 4% paraformaldehyde (PFA) immediately in 
theatre. The cadaveric donor tissues were fixed in 4% PFA within 24 to 48hours 
from harvesting.
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Chapter 3 
Results
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3.1 Detection of BDNF protein in cultured Muller cell lysates
To determine the expression of BDNF at protein level in cultured human 
Muller cells, Western blot analysis of both lysates and supernatants of 
MIO-M1 cell line were performed. Cell lysates examined at 24, 48, and 72 
after culture identified a band measuring approximately 40kDa (figure 3.1, 
lanes 2-4). The same band was also identified in the mouse brain extract 
(Santa Cruz Biotechnology, CA) used as positive control (figure 3.1, lane 
9). This indicated presence of BDNF pro-protein (see discussion). Two 
other non-specific bands were also identified at approximately 90 and 100 
kDa (figure 3.1, lanes 2-4 and 9). No bands were identified in the 
supernatants after 24 hours culture (figure 3.1, lane 5).
The expected size for BDNF monomer is approximately 14kDa but a band 
of this molecular weight was not detected in any of the Western blot 
experiments performed. Anti-BDNF antibody did not react with 
recombinant human NT-4 (lane 8) indicating no cross reactivity.
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Figure 3.1 Detection of BDNF by Western blot analyses of MIO-M1 cell
lysates and supernatants after cell culture for various time periods.
Lane orders;
1= Molecular weight ladder (Santa Cruz Biotechnology, CA, sc-2035),
2= lysate prepared after 24 hours culture 
3=lysate prepared after 48 hours culture 
4=lysate prepared after 72 hours culture 
5= 24 hours supernatant control,
6= 48 hours supernatant control,
7= 72 hours supernatant control,
8= Recombinant human NT-4,
9= Mouse brain extract,
10= Molecular weight ladder (Santa Cruz Biotechnology, CA, sc-2035)
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3.2 Western immuno-blot to detect NT4 in cultured Muller cell lysates and 
supernatants
These experiments did not detect NT4 protein in cell lysates and 
supernatants after 24 hours (not shown in the figure 3.2 presented here 
but studied in several experiments) 48 and 72 hours. There was also no 
detectable protein in the supernatant after 72 hours of cell culture. 
Experiments repeated several times under standard conditions detected 
the positive control protein (recombinant human NT4, R&D Systems, 
Mineapolis, MN, USA) at appropriate expected size of 14 kDa. It also 
identified a slower migrating protein at approximately 28 kDa, possibly 
NT4 dimer (figure 3.2).
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Figure 3.2 Western immunoblot to detect NT4 in cultured MIO-M1 cell 
lysates and supernatants.
Anti-NT4 antibody only reacted with the rhNT4 used as positive control. 
This antibody did not identify any proteins in cell lysates or supernatants.
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3.3 Detection of Truncated TrkB in cultured Muller cell lysates
W e next examined the expression of TrkB, the specific receptor for BDNF 
and NT4, by cultured MIO-M1 cells and analysed the supernatant and the 
lysates at various time points using Western blot technique. The antibody 
used (Santa Cruz, Biotechnology CA) reacts with both the full length and 
the truncated receptor as it targets the extracellular component of the 
receptor.
Two protein bands of similar size of approximately 80 kDa were detected 
at 96 hours after cell culture corresponding to the truncated isoform of the 
receptor (figure 3.3, lane 3). There was no clear band identifiable in the 
supernatants, however, a very faint trace could be seen at the same level 
as the lower band suggesting presence of the lower molecular weight 
truncated receptor in the supernatant in smaller quantities compared with 
that present in the cell lysates. No bands corresponding to the full-length 
receptor was identified (expected size of approximately 145 kDa). There 
was no suitable available positive control for this experiment.
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Figure 3.3 Detection of t-TrkB by Western blot analysis of MIO-M1 cell 
lysates and supernatants after cell culture at various time periods.
This figure shows that two strong and distinct bands were identifiable of 
approximately 80 kDa in the cell lysates following 96 hours of cell culture. 
Only a very faint band was detected in lysates prepared after 72 hours of 
cell culture as well in the supernatants after 96 hours. These bands would 
approximately correspond to the expected molecular size of truncated 
receptors.
Lane orders; 1= Molecular weight ladder (Santa Cruz, sc-2035), 2= Cell 
lysates after 72 hours of cell incubation, 3= Cell lysates after 96 hours of 
cell incubation, 4= Supernatants after 96 hours of cell incubation, 5= 
Negative control.
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3.4 PCR amplification of BDNF, NT4 and t-TrkB
To assess the expression of BDNF, NT4 and their receptor TrkB in full 
length as well as its truncated isoform at the mRNA level we performed 
RT-PCR.
mRNA extracted from MIO-M1 cell lysates was analysed using RT-PCR  
and the products showed distinct bands corresponding to the expected 
size for t-TrkB and BDNF (figure 3.4 and 3.5). GAPDH was used as the 
internal control and expected bands of 600bp were amplified. There was 
no NT4 detectable using this set of primers.
A separate set of primers were subsequently used to detect BDNF and 
NT4 which successfully demonstrated expression of both of these growth 
factors at the RNA level (figure 3.6). The intensity of NT4 bands detected 
was uniform at 24 and 48 hours after cell culture. Similarly the band 
intensity corresponding to BDNF expression at 24, 48 and 72 hours 
suggested there was comparable amount of RNA expression at these time 
points. No bands were detected in negative controls.
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Ladder GAPDH t-TrKB BDNF NT4 -ve control
600 bp 
500 bp 
400 bp
300 bp
expected GAPDH product size; 600 bp 
expected t-TrKB product size; 430 bp 
expected BDNF product size; 390 bp
Figure 3.4 Detection of BDNF and t-TrkB by RT-PCR.
RNA specimens extracted from MIO-M1 cell lysates were analysed using 
RT-PCR and the products show distinct bands corresponding to the 
expected size for t-TrkB (lane 3) and BDNF (lane 4). GAPDH was used as 
the internal control and the expected band of 600bp was amplified (lane 
2). There was no NT4 detectable using this method and no bands were 
detected in the negative control lane.
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ladder -ve control TrkB t-TrkB
Figure 3.5 RT-PCR result demonstrating expression of t-TrkB mRNA by 
cultured MIO-M1 cells.
Expected product size of 430 bp was detected in lane 4 confirming mRNA 
expression of t-TrkB by cultured MIO-M1 cells. There was no detectable 
product for the full length receptor.
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Figure 3.6 Detection of BDNF and NT4 in cultured MIO-M1 Muller cells by 
RT-PCR.
In this experiment a separate pair of primers to those used previously (in 
figure 3.4) was used to detect mRNA expression of BDNF and NT-4 by 
cultured Muller cells. Bands of 202bp corresponding to the expected size 
for NT4 RT-PCR product were detected in both lanes 2 and 3. Similarly, 
expected band size of 222 bp was detected in lanes 4-6 confirming mRNA 
expression of BDNF. There were no detectable bands in negative controls 
(lanes 7 and 8).
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3.5 PDGF supplement up-regulates the expression of BDNF in cultured 
MIO-M1 cells
Additions of PDGF to the culture medium (50ng/ml) lead to an increase in 
intensity of the detectable band corresponding to BDNF expression (figure 
3.7). This did not appear to have affected the expression of the internal 
control GAPDH or the t-TrkB. This would suggest an increase in mRNA 
expression of BDNF but not t-TrkB. The intensity of bands in both lanes 6 
and 7 (figure 3.7) was similar suggesting no detectable effect on GAPDH 
expression by addition of PDGF. There were no detectable bands 
corresponding to expected size for NT-4 amplification. No RT-PCR  
products were detected in negative control lanes (figure 3.7 lanes 10 and 
11 ).
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Figure 3.7, RT-PCR products showing the effect of PDGF (Sigma, 50 ng/ml) 
on BDNF and t-TrkB expression (figure A). Density measurements for RT- 
PCR products (figure B).
Addition of PDGF to the culture medium lead to an apparent increase in 
BDNF expression as evident by higher intensity band detected in lane 3 
compared to that in lane 2. This did not appear to have affected the 
expression of the internal control GAPDH (lanes 6 and 7) or the t-TrkB 
(lanes 4 and 5).
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Lane orders in figure 3.7 A;
1= ladder
2=BDNF (control), expected size 222 bp
3=BDNF (plus PDGF supplement), expected size 222bp
4=t-TrkB (control), expected size 161 bp
5=t-TrkB (plus PDGF supplement), expected size 161 bp
6=GAPDH (control)
7=GAPDH (plus PDGF supplement)
8= NT4 (control), expected size 202bp
9=NT4 (plus PDGF supplement), expected size 202bp
10 and 11=Negative controls.
In figure 3.7 B the intensity of the RT-PCR bands was quantified in 
arbitrary units using the Kodak computer software programme KDS1D -  
version 2.0.
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3.6 Phenotypic distribution of BDNF, NT4 and t-TrkB in cultured cells
We next examined the expression of BDNF in cultured MIO-M1 cells after 
fixing them in PFA to identify the pattern of distribution and localisation of 
this factor within the cells.
BDNF was detected within the cells and distribution was found to be 
mainly peri-nuclear with some protein detectable in the cell processes. 
Staining for BDNF showed a granular appearance (figures 3.8 panel A). 
NT4 protein expression had similar appearance and distribution as BDNF 
(figure 3.8 panel B). Protein expression of the truncated receptor, t-TrkB, 
was mainly at the peri-nuclear area and again had a granular appearance 
(figure 3.8 panel C).
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Figure 3.8 Scanning laser confocal image of cultured MIO-M1 cells stained 
with anti BDNF (panel A), anti NT4 (panel B) and anti t-TrkB (panel C) 
antibodies.
These images show immunostaining of BDNF, NT4 and t-TrkB with a 
granular appearance. Their distribution was mainly peri-nuclear with some 
protein staining detectable in the cell processes. Scale bars=20pm.
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3.7 Immunolocalisation of BDNF in the normal human retina
In order to localise BDNF staining in human retina normal donor eyes 
retinas were examined and the peripheral retina was stained by 
immunohistochemical methods using anti BDNF antibody. Rods and 
nuclear layers were counter stained to identify the retinal structures and to 
identify any possible co-localisations. Scanning laser confocal images 
showed BDNF expression on the nerve fibre and the photoreceptor layers. 
The intensity of staining for this factor was generally weak. There was also 
co-localisation of BDNF and rhodopsin suggesting the presence of this 
growth factor in rods (figures 3.9). There was no detectable BDNF in the 
inner and outer nuclear layers. Figure 3.10 shows another normal retina 
demonstrating similar pattern of staining for BDNF in photoreceptor and 
nerve fibre layers.
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Figure 3.9 Double-labeled immunostaining using antibodies to BDNF (red) 
and rhodopsin (green).
Panel A shows pattern of BDNF staining. Panel B demonstrates staining 
of the photoreceptors (Rods).The merged image of A and B is shown in 
the panel C. Panel D shows the magnified section of photoreceptors. In 
normal human retinas there is expression of BDNF at the photoreceptor 
(PR) and the nerve fibre layers (NFL). Panels C and D demonstrate the 
co-localisation of BDNF with rhodopsins suggesting the presence of this 
growth factor in rods. Scale bars= 100pm.
Figure 3.10 Normal human retina immunostaining using antibodies to BDNF 
(red) and rhodopsin (green). Nuclei are stained with To-Pro3-Iodide (blue). 
This image demonstrates week staining for BDNF at the NFL and the PR 
layers in normal human retina. There is no staining for BDNF at the 
nuclear layers.
PR=photoreceptors, ONL=outer nuclear layer, INL=inner nuclear layer, 
NFL=Nerve fibre layer. Scale bar= 100pm.
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3.8 Immunolocalisation of NT4 in the normal human retina
To determine the expression and distribution of NT4 in the normal human 
retina double staining of donor sections were examined with confocal 
scanning laser microscope. This showed positive staining for NT4 mainly 
in the nerve fibre and photoreceptor layers (figure 3.11). The level of 
staining was generally low in the sections examined but stronger than 
those observed in sections stained for BDNF.
Figure 3.11 Double-labeled immunohistochemistry using antibodies to NT4 
(red) and rhodopsin (green).
Panel A shows staining for NT4 (red) mainly in the nerve fibre layer (NFL) 
and photoreceptor (PR) layer. Panel B shows staining for rhodopsin and 
panel C is the merged image of panels A and B demonstrating a degree of 
co-localisation of NT4 with rhodopsin. PR=photoreceptors, NFL=nerve 
fibre layer. Scale bars=100pm.
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Figure 3.12 Normal human retina immunostaining using antibodies to NT4 
(red) and rhodopsin (green). Nuclei are stained with To-Pro3-Iodide (blue). 
This scanning confocal laser images of normal human retina shows that 
NT4 is mainly expressed in the nerve fibre layer and there is no nuclear 
staining associated with this protein. PR=photoreceptors, ONL=outer 
nuclear layer, INL=inner nuclear layer, NFL=Nerve fibre layer. Scale bar= 
100pm.
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3.9 Negative controls
Negative controls used for immunostaining studies including normal 
human retina sections and PVR retinectomy sections did not show any 
staining apart from the expected nuclear staining (figure 3.13). Rabbit IgG 
(DAKO, Golstrup, Denmark) and Mouse IgG (Sigma, St. Lois, MO, USA) 
were used at the same concentration as the primary antibodies for 
negative controls. A second negative control was also prepared without 
addition of primary antibodies.
Figure 3.13 Negative control specimens used in immunostaining studies.
This figure shows two of the PVR retinectomy sections (A and B, sample 
2, table 3.2) and one of the normal human sections (C) with staining of the 
nuclear layers of the retina with To-Pro3-iodide in blue. There is no other 
staining observed in these specimens. ONL= Outer nuclear layer, INL= 
Inner nuclear layer, GCL= Ganglion cell layer. Scale bar= 100pm.
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3.10 BDNF expression in PVR retinectomy sections
Eight retinectomy sections from patients with PVR were analysed to 
investigate any change in degree and pattern of expression of BDNF.
An increased distribution of staining for BDNF throughout the entire retinal 
section was detected but the intensity of staining was similar to the normal 
retinal sections studied (figures 3.14 and 3.15). There was no staining for 
BDNF at the nuclear layers. Photoreceptor outer segments were found to 
be much less prominent in the PVR retinectomy sections (figures 3.14 and 
3.15).
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Figure 3.14 Normal (A and B) and PVR retinectomy (C and D) sections 
immuno-labelled using antibodies to BDNF (red) and rhodopsin (green). 
Nuclear staining is with To-Pro3-Iodide (blue).
Panels A and B show the pattern of staining in the normal human tissues 
for comparison. Panels C (sample 1, table 3.2) and D (sample 2. table 3.2) 
are PVR retinectomy tissues demonstrating a disrupted retinal structure 
due to PVR. It also shows prominent reduction in the photoreceptor layer 
particularly in panel C. The intensity and pattern of staining for BDNF (red) 
in PVR sections was very similar to normal specimens. ONL= Outer 
nuclear layer, INL= Inner nuclear layer, GCL= Ganglion cell layer. Scale 
bar= 100pm.
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mFigure 3.15 PVR retinectomy section double-labeled using antibodies to 
BDNF (red) and rhodopsin (green). Nuclear staining is with To-Pro3-Iodide 
(blue).
This section (sample 4, table 3.2) shows a more widespread staining for 
BDNF (red) in the PVR retinectomy specimen compared to the normal 
retina shown in figure 3.10. The intensity of staining remained similar to 
donor retina and only the extent of BDNF distribution seem to have been 
altered extending throughout the whole thickness of the retina. 
PR=photoreceptor layer, ONL= Outer nuclear layer, INL= Inner nuclear 
layer. Scale bar=100pm.
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3.11 NT4 expression in PVR retinectomy sections
To determine the level of expression and distribution of NT4 in PVR 8 
retinectomy specimens were examined. These sections showed a marked 
increase in both the intensity and the distribution of NT4 extending the 
entire thickness of the retina (figures 3.16 A-C). NT4 distribution at the 
outer retina was however observed to be abruptly limited to where 
photoreceptor outer segment staining started (figure 3.17). This level 
corresponds to the outer limiting membrane (OLM), the outer most limit of 
distribution of the Muller cells.
This pattern of staining and the morphology of the cells stained with NT4 
are very suggestive of the presence of this protein in the Muller cells 
(figure 3.18 and 3.19).
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Figure 3.16 PVR retinectomy 
sections double-labeled using 
antibodies to NT4 (red) and 
rhodopsin (green). Nuclear 
staining is with To-Pro3-Iodide 
(blue).
These images demonstrate NT4 
staining (red) in three different PVR retinectomy sections (panel A=sample 
3, panel B=sample 4, and panel C=sample 7 in table 3.2). Compared to 
the normal retina shown in figure 3.12, there is extensive and widespread 
expression of NT4 through the whole thickness of the retina with high 
intensity staining. Scale bar= 100pm.
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Figure 3.17 PVR retinectomy section double-labeled using antibodies to NT4 
(red) and rhodopsin (green). Nuclear staining is with To-Pro3-Iodide (blue). 
This PVR retinectomy section (sample 5, table 3.2) demonstrates NT4 
staining (red) which is abruptly limited at the same level where 
photoreceptors outer segment staining is detected (green). This location 
corresponds to the outer limiting membrane (OLM) of the retina where 
Muller cell processes end in the outer aspect of the retina. This pattern of 
staining would also suggest an intercellular location for NT4 as the 
staining is not spread in the extracellular space. Scale bar= 100pm.
Figure 3.18 PVR 
retinectomy section
double-labeled using
^elJ|ller antibodies to NT4 (red).
Nuclear staining is with 
To-Pro3-lodide (blue). 
This PVR retinectomy 
specimen (sample 6, 
table 3.2) shows NT4 staining (red) distributed through the entire
thickness of the retina (arrow) corresponding to that expected from Muller
cells distribution. The morphology of the cells stained is also similar to 
Muller cells. Scale bar= 100pm.
Muller cell
L >
Figure 3.19 Magnified view of figure 3.18.
This image shows cell morphology of remarkable similarity to a single 
Muller cell with its characteristic cell processes and spanning across inner 
and outer nuclear layers. ONL= outer nuclear layer, INL=inner nuclear 
layer. Scale bar= 50pm.
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3.12 NT4 staining in PVR co-localises to Muller cells
To further investigate the location of NT4 staining in the PVR specimens 
we co-stained the sections with both GFAP and NT4. GFAP is generally 
up-regulated in the retina in PVR and is a known marker for retinal glial 
cells. In the studied sections there was GFAP staining extending the 
whole thickness of the retina as would be expected in PVR (figures 3.20 
and 3.21). This experiment confirmed co-localisation of GFAP with NT4 
providing evidence that up-regulated NT4, observed in PVR sections 
studied, is contained within Muller cells.
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Figure 3.20 PVR retinectomy sections double-labeled using antibodies to NT4 
(red) and GFAP (green). Nuclear staining is with To-Pro3-Iodide (blue).
The morphology of cells staining for NT4 and their co-localisation with 
GFAP is highly suggestive of NT4’s presence within Muller cells. Scale 
bars=100pm.
B c
Figure 3.21 Magnified view of figure 3.20.
These images show a section from an eye with PVR co-staining for GFAP 
(panel A, green stain) and NT4 (panel B, red stain). Panel C shows 
nuclear staining (blue) to demonstrate the retinal architecture. It shows 
very good co-localisation of NT4 and GFAP (panel C) providing evidence 
for intracellular distribution of NT4 in Muller cells.
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3.13 TrkB expression in normal human retina
TrkB receptor expression in the normal human retina was examined by 
double staining the sections with the antibody for the full length receptor. 
There was minimal staining at the nerve fibre and photoreceptor layers in 
the studied sections. No staining was observed at the nuclear layers.
W k
Figure 3.22 Normal human retina immunostained using anti TrKB antibody 
(red) and anti rhodopsin antibody (green). Nuclear staining is with To-Pro3- 
Iodide (blue).
These images show minimal staining for TrkB (red) receptor detectable at 
the ganglion cell layer. There is no staining at the nuclear layers. 
PR=photoreceptor layer, ONL=outer nuclear layer, INL=inner nuclear 
layer, NFL=nerve fibre layer. Scale bar= 100pm.
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3.14 TrkB expression in PVR retinectomy sections
PVR retinectomy sections were examined to assess pattern and level of 
expression of TrkB compared to the normal retina. No staining was 
detectable in any of the sections studied. There were also no detectable 
truncated receptors using this method of staining.
PR
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Figure 3.23 PVR retinectomy section immunostained using anti TrKB 
antibody (red, no staining here) and anti rhodopsin antibody (green). 
Nuclear staining is with To-Pro3-Iodide (blue).
This PVR specimen (sample 3, table 3.2) shows no staining for the 
receptor. Photoreceptor receptor staining is present (green) suggesting 
that technical problems with staining are unlikely. Scale bar= 100pm.
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3.15 t-TrkB mRNA levels in cultured MIO-M1 cells supplemented with NT4
We next studied the possible effect of increased NT4 levels on the 
expression of t-TrkB mRNA. Cultured MIO-M1 cells supplemented with 
various concentrations of rhNT4 for 5 days were assayed using RT-PCR. 
There were detectable bands corresponding to the expected size for t- 
TrkB for all concentrations of NT4 used in the experiments. The strongest 
band was detected with NT4 concentration of 10ng/ml and the weakest 
intensity band was seen at the concentration of 1ng/ml. When 50ng/ml of 
NT4 used the band intensity produced an intermediate signal (figure 3.24). 
It appears that the lower (1ng/ml) and higher (50ng/ml) concentrations of 
NT4 used in this experiment may have the same effect on the level of t- 
TrkB production and reduce its mRNA production.
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Figure 3.24 t-TrkB mRNA levels in cultured Muller cells with NT4 
supplement (figure A). Density measurements for RT-PCR products (figure 
B).
RNA was extracted after 5 days of cell culture. The band intensity in lane 
4 (sample treated with 10ng/ml NT4) was strongest. Both lower (lane 3) 
and higher (lane 5) concentrations of the NT4 supplement to the culture 
medium resulted in detection of lower intensity bands compared to lane 4. 
Lane orders; 1= control with no NT4 added to the culture medium, 2= 
negative control, 3= 1ng/ml NT4 added to the culture medium, 4= 10ng/ml 
NT4 added to the culture medium, 5= 50ng/ml NT4 added to the culture 
medium (figure A). Intensity of the RT-PCR bands was quantified in 
arbitrary units using the Kodak computer software programme KDS1D -  
version 2.0 (figure B).
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3.16 Neurotrophins expression in retinas of patients with choroidal 
melanoma and in controls
No immunostaining for NT-3 or BDNF was detected in any of the retinas 
from eyes that had undergone laser treatment or in controls (Table 3.1). 
Immunostaining for NT4 however was observed in both the inner and 
outer nuclear and ganglion cell layers in 2 out of three retinas of 
melanoma patients and all normal controls (figure 3.25A, Table 3.1). 
However, in the melanoma eye, which underwent laser photocoagulation 
1 day prior to enucleation, there was a marked decrease in the 
immunostaining for this neurotrophin in the outer nuclear cell layer at the 
site of the laser burn (Table 3.1, figure3.25B). In eyes enucleated 6 days 
after laser treatment, the outer nuclear layer was atrophic at the laser site, 
but occasional cells still present, were negative for this molecule 
(figure3.25C).
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Figure 3.25: Pattern of NT4 staining in normal and laser treated retinas 
H&E and anti-NT4 stain (from Ghazi-Nouri SM et a l 2003).
FigA: Normal retina showing intense NT4 staining in inner and outer 
nuclear layers, 50X magnifications. FigB: one day post laser showing 
reduced NT4 staining in ONL. This reduced staining is confined to the 
extent of laser injury, 50 X magnifications. Fig C: six days post laser 
showing atrophic ONL at the site of laser with only a few cells seen and 
reduced NT4 staining, 100X magnification. RPE=retinal pigment 
epithelium, ONL=outer nuclear layer, INL=inner nuclear layer, 
GCL=ganglion cell layer.
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3.17 GFAP and CD68 expression in eyes with choroidal melanoma and in 
controls
Intense staining for GFAP was observed throughout all the retinal layers in 
all melanoma eyes (Figure 3.26A) and no change in this expression was 
found in lasered eyes (Figure 3.26B). In contrast, retina from normal 
controls showed minimal staining for GFAP, which was limited to the ILM, 
ganglion cell and nerve fibre layers (Figure 3.26C).
Staining for CD68 was observed on laser damaged retinal pigment 
epithelial cells and on underlying choroidal inflammatory and pigmented 
cells. Cells positive for this marker were not observed in any of the control 
specimens (Fig. 3.27A). In the eye enucleated 1 day after laser treatment 
there was a marked localized accumulation of polymorphonuclear 
leucocytes, mononuclear cells and pigmented choroidal cells at the laser 
site (Figs. 3.27B). In addition, a moderate number of scattered cells 
staining for CD68 were observed in the choroid, and mild RPE cells 
staining for CD68 was seen (Fig 3.27B). In the eye enucleated 2 days 
after laser, a more intense infiltration of CD68 positive cells, some of 
which formed an incomplete perivascular cuff, was observed, and RPE 
cells displayed a more intense CD68 staining than on day 1 (Figure 
3.27C). In contrast, intense staining for CD68 was observed on 
mononuclear and choroidal pigmented cells as well as RPE cells 6 days 
after laser treatment (Figs 3.27D).
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Figure 3.26 Pattern of GFAP staining in malignant melanoma, laser treated 
and normal Retinas. H&E and anti-GFAP stain (red) (from Ghazi-Nouri SM 
et al 2003).
Fig.A: GFAP staining throughout all layers of retina in malignant 
melanoma, 50X magnifications. Fig.B: GFAP staining throughout all layers 
of the lasered retina (1 day post laser), 50 X magnifications. Fig.C: GFAP 
staining of the inner limiting membrane, Ganglion cell and nerve fiber layer 
in normal retina, 50 X magnifications. ONL=outer nuclear layer, INL=inner 
nuclear layer, GCL=ganglion cell layer.
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Figure 3.27 Pattern of CD68 staining in normal and laser treated retinas. 
H&E and anti-CD68 antibody (from Ghazi-Nouri SM et al 2003).
Fig.A: Normal retina with no CD 68 staining in the choroid, 50X 
magnifications. Fig.B: CD68 staining in the choroid 1 day post laser, 100 X 
magnifications. Fig.C: CD68 staining 2 days post laser. Note CD68 
positive cells associated with RPE and perivascular cuff, 100 X 
magnifications. Fig.D: CD68 staining 6 days post laser showing more 
intense staining compared to days one and two, 100X magnifcation. 
RPE=retinal pigment epithelium, ONL=outer nuclear layer, INL=inner 
nuclear layer.
112
Specimen
number
Origin of 
specimen
Laser prior to
enucleation
(days)
NT4 GFAP CD68
1 Melanoma 1 + a +++ c +
2 Melanoma 2 + a +++ c +
3 Melanoma 6 + a +++ c ++
4 Melanoma 6 + a +++ c ++
5 Melanoma n/a +b +++ c —
6 Melanoma n/a + D +++ c —
7 Melanoma n/a — +++ c —
8 Cadaveric
donor
n/a + + D '+ d
9 Cadaveric
donor
n/a + + D + d
10 Cadaveric
donor
n/a + + D + a
Table 3.1 Immunohistochemical staining of lasered and control retinas 
Intensity of staining: +++ = strong, ++ = moderate, + = mild, -  = negative 
a Staining reduced in outer nuclear layer at the site of the laser burn,b 
staining of inner and outer nuclear layers of the retina,c staining 
throughout the whole retina,d scattered staining of cells predominantly in 
the nerve fibre layer.
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Sample 
(age,sex)
Condition BDNF
(staining
distribution)
NT4
(staining
distribution)
TrkB
(staining
distribution)
t-TrkB
(staining
distribution)
1
(80,F)
PVR + (ILM to 
OLM)
+++ (ILM 
to OLM)
2
(56,F)
PVR + (ILM to 
OLM)
++ (ILM to 
OLM)
3
(72,F)
PVR + (ILM to 
OLM)
+++ (ILM 
to OLM)
4
(67,F)
PVR + (ILM to 
OLM)
+++(ILM to 
OLM)
5
(70,M)
PVR Sample lost
during
processing
+++ (ILM 
to OLM)
6
(52,M)
PVR + (PR) +++ (ILM 
to OLM)
7
(55,M)
PVR + (NFL and 
PR)
++ (ILM to 
OLM)
8
(38,M)
PVR + (ILM to 
OLM)
+++ (ILM 
to OLM)
9
(55,M)
Cadaveric
donor
+ (NFL and 
PR)
+ (NFL and 
PR)
+ (NFL and 
PR)
+ (NFL and 
PR)
10
(50,M)
Cadaveric
donor
+ (NFL and 
PR)
+ (NFL and 
PR)
+ (NFL and 
PR)
+ (NFL and 
PR)
11
(75,M)
Cadaveric
donor
+ (NFL and 
PR)
+ (NFL and 
PR)
+ (NFL and 
PR)
+ (NFL and 
PR)
Table 3.2 Immunostaining intensity and distribution for BDNF, NT4, TrkB
and t-TrkB observed in PVR retinectomy sections and normal controls.
ILM=inner limiting membrane, OLM=outer limiting membrane, 
NFL=nerve fibre layer, PR=photoreceptors. Intensity of staining: +++ = 
strong, ++ = moderate, + = mild, -  = negative.
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Sample 
(age,sex)
Aetiology 
of RD
Silicone
oil
tamponade
Number o f VR  
procedures 
prior to 
sample 
analysis
Time between 
first RD surgery 
and retinectomy 
specimen 
(months)
Comments
1
(80,F)
RRD Yes 2 17 APVR, SRM
2
(56,F)
RRD Yes 4 1 PVR, ERM
3
(72,F)
RRD
(inferior
RD)
Yes 3 3 PVR, Total RD
4
(67,F)
RRD No 2 2 APVR
5
(70,M)
RRD Yes 3 12 PVR, Inferior RD
6
(52,M)
RRD Yes 4 2 PVR
7
(55,M)
RRD Yes 4 3 PVR, Inferior 
TRD, ERM
8
(38,M)
Penetrating
injury
Yes 3 27 PVR, Subtotal 
RD, SRM
Table 3.3 Details of patients and retinectomy tissues studied.
RD=retinal detachment, RRD=rhegmatogenous RD, TRD=tractional RD, 
PVR= proliferative vitreoretinopathy, APVR= anterior PVR, 
SRM=subretinal membrane, ERM=epiretinal membrane.
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Chapter 4 
Discussion
Exogenous BDNF is known to rescue ganglion cell death after optic nerve 
injury (Mansour-Robaye S 1994). Its mechanism of action is believed to 
be indirect via glial cells in the retina. Muller cells are the principal glial 
cells of the human retina and span its entire thickness, being in direct 
contact with every type of neuron in the retina. Wahlin KJ et al (2000) data 
suggest that BDNF, CNTF, and FGF2 may exert their effects on 
photoreceptors by acting indirectly through activation of Muller cells and 
perhaps other non photoreceptor cells. Although there are reports in the 
literature suggesting the existence of NTs in various parts of the eye 
including the lamina cribrosa (Lambert W 2001) and the trabecular 
meshwork (Wordinger RJ 2000), the exact location of NT production in the 
retina has not been fully characterised.
The findings presented here confirm the only previous report (Oku H 
2002) that cultured human Muller cells express BDNF at mRNA level. In 
their study, Oku et al investigated primary cultured Muller cells whereas 
the present study examined the expression of this factor by a Muller cell 
line. Oku et al also observed that cultured Muller cells expressed NGF and 
NT3 but they did not investigate the expression of NT4, and there is no 
other report in the literature indicating the expression of NT4 by human 
Muller cells. The present results however demonstrate that cultured MIO- 
M1 cells express NT4 at mRNA level. The expression of NT4 as judged by 
RT-PCR experiments was much lower than that of BDNF. This was 
inferred from the observation that bands corresponding to the NT4 
products were less intense than those of the BDNF products resulting 
from the amplification of equal amounts of mRNA. Quantitative PCR
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techniques were not used here to demonstrate this difference accurately, 
nevertheless, control amplification of the house keeping gene GAPDH 
showed similar levels of mRNA in the samples investigated, for which 
differences in the intensity of the bands observed strongly suggests that 
the MIO-M1 levels of mRNA expression coding for NT4 were lower than 
those coding for BDNF.
It was of interest that although mRNA coding for NT4 was detected in the 
cells, protein expression for this molecule could not be identified by 
Western blot analysis of cultured MIO-M1 cell lysates or supernatants. It is 
possible that the amount of protein produced was below detectable levels 
using the methods described in this study. This may be explained by the 
low mRNA levels of NT4 detected in the RT-PCR experiments. Other 
possible explanation is that translation of mRNA into protein did not occur 
under the conditions used in the study. However, this is unlikely since 
immunostaining for the NT4 protein in fixed Muller cells demonstrated 
positive staining for this molecule (see below) and Western blot analysis of 
the control protein yielded a band corresponding to the molecular weight 
for NT4 (14 kD).
Anti-BDNF antibodies detected a band of approximately 40 kDa in 
Western blot experiments. This is not the expected band for the monomer 
of this protein and probably represents the pro-protein which has been 
reported in other studies (Seidah NG 1996, Fayard B 2005). All NTs are 
generated from 31-35 kDa precursors, which are then cleaved 
intracellularly to produce the mature molecule. Although the band detected 
in the present study appears to be of a slightly larger size, the fact that a
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band of the same molecular weight was detected in the appropriate 
positive control (mouse brain extract) suggests that the antibody had 
positively identified BDNF protein. Failure to detect BDNF at its 
monomeric size may be due to its absence in the MIO-M1 cell lysates or it 
may be that there was very small amount of this protein present and the 
abundance of the pro-protein had led to only one identifiable band.
BDNF is reported to protect ganglion cells from ischemic stress (Unoki K, 
and LaVail MM 1994) and after an optic nerve injury (Peinado-Ramon P 
1996, Mansour-Robaye S 1994). There is also evidence suggesting that 
BDNF and NGF can rescue photoreceptor cells in animal models of retinal 
detachment (Lewis GP 1999) and retinal light damage (Harada T 2000), 
respectively. Expression of this neurotrophic factor by Muller cells 
suggests a neuroprotective role for these cells. The amount of BDNF 
production can also be altered in inflammatory conditions. This was 
demonstrated in this study when PDGF supplement was added to the 
culture medium. This resulted in an increased expression of mRNA coding 
for BDNF, suggesting that neurotrophic factors expression may be 
induced by this factor, which is highly upregulated during retinal 
inflammatory processes. PDGF is released from aggregated platelets at 
wound sites and acts as a chemo-attractant and mitogen for many cell 
types that participate in wound repair, including monocytes, macrophages, 
and fibroblasts (Pierce GF 1991). Exogenous PDGF promotes increased 
wound strength (Pierce GF 1989 and 1991) and is also known to play an 
important role in proliferative retinopathies (Smith-Thomas L 1996). It 
could therefore be expected that elevated expression of BDNF and other
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NTs may be found in proliferative vitreoretonopathy. There are no 
previous studies demonstrating that these factors are increased during the 
development of this condition, and the present study shows that both 
BDNF and NT4 expression is highly increased in human PVR tissues as 
shown by immunohistochemistry and scanning confocal laser images 
(further discussed below).
Immunostaining of fixed Muller cells demonstrated intracytoplasmic 
presence of BDNF and NT4 in a similar pattern of distribution; mainly 
granular perinuclear with some positive staining in the cell processes. 
Presence of trophic factors within Muller cells further confirms suggestions 
that these cells exert play an important role in neural support. It has 
already been suggested that the trophic effects of NTs on photoreceptors 
may be exerted indirectly via Muller cells (Wahlin KJ 2000). It has been 
postulated that these trophic factors are transported throughout the whole 
thickness of the retina within the Muller cells (von Bartheld 2001), and that 
NTs may be internalised by binding to the truncated receptors (Eide FF 
1996). Internalised NTs are not necessarily degraded and can be targeted 
for release or for packaging in vesicles for anterograde axonal transport 
after internalisation (von Bartheld 2001). Muller cells, spanning the entire 
thickness of the retina have structural advantage to achieve this task.
This study demonstrated expression of the truncated isoform of the TrkB 
receptor by MIO-M1 cells both at the mRNA and protein levels. The role of 
truncated TrkB is believed to be the internalisation of its ligands and to 
function as an inhibitory modulator of neurotrophin responsiveness (Eide 
FF 1996). However, this study’s results did not show expression of the full-
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length receptor by these cells. This contrasts with that reported by Oku et 
al (2002) who showed mRNA expression of the full-length receptor (TrkB 
and TrkC) by cultured human Muller cells. Oku et al did not use a cell line 
and it is possible that cell line used in the present study does not express 
the full-length receptor. Co-expression of the truncated TrkB and both 
BDNF and NT-4 found in this study also suggests an auto-regulatory 
function in these cells. In relation to the detection of TrkB, this study has 
some limitations, including lack of a suitable positive control for TrkB in 
RT-PCR and Western blot analysis. However, controlled amplification of 
GAPDH yielded a band with the expected size of 600bp and the RT-PCR  
product exhibited the molecular weight of the expected size. This however 
suggests that TrkB detection was specific, and it is supported by the 
Western blot analysis of this receptor, wich yielded bands of molecular 
weight corresponding to t-TrkB.
There is extensive non-neuronal localization of truncated TrkB-T1 
receptors in the central nervous system (Fryer RH 1997). There is also an 
up-regulation of the truncated receptors by CNS glial cells in response to 
injury leading to the speculation that these receptors may sequester BDNF 
and NT-4/5 to reduce their local availability and, thus, limit axonal 
sprouting (Fryer RH 1997). Findings from other investigators, however, 
suggested that truncated TrkB-T1 mediated neurotrophic-evoked calcium 
signalling in glial cells (Rose CR 2003).
Although interesting observations with respect to the expression of various 
NTs and its receptors by the Muller glial cell line MIO-M1 were observed in 
this study, it might be possible that differences between these cells and
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freshly isolated cells from the retina may exist. Further investigations are 
needed to clarify this issue.
In this study the expression of receptors in the retinectomy specimens was 
not detected, unlike the retinal specimens from normal donor eyes, which 
show a mild expression of this molecule. The intracellular pattern of 
distribution of TrkB in cultured Muller cells is consistent with previous 
reports that in some projection neurons from the central nervous system, 
Trk receptors appear to be largely sequestered in intracellular vesicles 
(Meyer-Franke A 1998). The same study also suggested that only in the 
presence of a second signal, such as cAMP or Ca2+, the receptors are 
inserted efficiently into the plasmalemma.
Down-regulation of TrkB may be a direct result of the well recognised 
phenomenon whereby excessive presence of ligand leads to consumption 
of the available receptor and also its reduced synthesis. Results in the 
present study suggest that varying the concentrations of NT4 can 
influence the amount of the t-TrkB mRNA synthesis. Addition of human 
NT4 to MIO-M1 cells cultured medium resulted in changes to the level of t- 
TrKB mRNA detected by RT-PCR. Addition of human NT4 at 
concentrations of 1ng/ml and 50ng/ml to cultured MIO-M1 cells resulted in 
a reduced t-TrkB mRNA production compared with that observed when 
10ng/ml of the NT4 supplement was added. It is not clear what level of 
growth factor may be present under pathologic conditions and this 
experiment merely demonstrates that NT4 concentration can influence 
mRNA expression of t-TrkB suggesting a negative regulatory effect of NT4 
on TrkB receptors. This observation is supported by previous reports that
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show a down regulation of full length TrkB in response to BDNF exposure 
both in vitro and in vivo (Frank I 1996, Knusel B 1997). In contrast, Kunsel 
et al only observed down regulation of the full length TrkB receptor and 
not the truncated isoform.
Reduced receptor expression was associated with increased expression 
of both BDNF and NT4 in all 8 PVR retinectomy sections investigated in 
the present study. Staining for BDNF in all tissues examoined showed 
minimal increase with extensive distribution of this protein throughout the 
retina. In contrast NT4 was markedly up regulated, showing widespread 
and intense distribution throughout the whole thickness of the retina. This 
staining abruptly stopped at the level where photoreceptor outer segments 
started i.e. at the level of the outer limiting membrane. This pattern of 
distribution suggested that NT4 was most likely expressed by Muller cells. 
Furthermore the morphology and distribution of stained cells expressing 
NT4 was very similar to Muller cells. Co-localisation of NT-4 and GFAP 
confirmed the presence of NT-4 within Muller cells.
Reduced availability of receptors would result in diminished effectiveness 
of NTs. Where exogenous NT factors are introduced to promote neuronal 
survival, it is also important to consider whether receptors are synthesised 
and expressed to utilise their ligands. Cheng et al (Cheng L 2002) have 
shown that the positive short-term effect of endogenous BDNF in ganglion 
cell survival can be enhanced when the appropriate receptor is also 
administered at the same time. This finding follows their observation that 
NT receptors are down regulated following optic nerve injury.
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In retinal injury there is hypertrophy of glial cells and enhanced 
immunoreactivity for GFAP (Bignami A 1979, Osborne NN 1991). This is 
illustrated by the study of Honjo et al (Honjo M 2000), who observed that 
expression of GFAP and ciliary neurotrophic factor (CNTF) in Muller cells 
is upregulated following an intravitreal injection of N-methyl-D-aspartate 
(NMDA). This indicates that Muller cells express neurotrophins in 
response to NMDA retinal toxicity. This is consistent with the present 
findings that neurotrophic factor upregulation can be observed following 
retinal damage.
Immunohistochemical findings on paraffin embedded sections in this study 
showed that normal human retina expresses NT4 at the level of outer 
nuclear layer (ONL), inner nuclear layer (INL) and ganglion cell layer 
(GCL) and that NT4 expression was down-regulated at the site of laser 
burns when examined at 1, 2 and 6 days post-laser. The degree of down 
regulation was more marked in the eyes enucleated 6 days after laser 
treatment and less on those enucleated after 1-2 days. These 
observations suggest that NT4 down regulation may be either secondary 
to local cell damage at ONL level or it may reflect a true reduction in NT4 
expression in cells normally producing these proteins.
There was a difference in the pattern of distribution of NT4 observed 
between paraffin embedded and PFA fixed samples; in parafin embedded 
control samples NT4 staining is observed in the inner and outer nuclear 
layers whereas in PFA fixed control samples the staining is more 
prominent in the nerve fibre and photoreceptor layers. This may be due to 
one or combination of several factors; Anti NT4 antibodies used in these
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two sets of experiments were from two different suppliers and their 
specificity might be different. Furthermore different techniques were 
employed to prepare the samples prior to imaging. PFA fixation tends to 
have better preservation of epitopes whereas paraffin may have 
deleterious effects by masking some epitopes.
Retinal specimens from melanoma eyes showed reduced intensity of NT4 
staining in 2 samples and absent NT4 staining in one case. This suggests 
reduced NT4 production, increased NT4 degradation or a combination of 
both. It is also possible that the observed GFAP up-regulation, indicating 
Muller cells reactivity, in melanoma and laser treated retinas is associated 
with the reduced NT4 staining. In vitro studies suggest that there is an 
increased sequestration of BDNF and NT4 at the site of reactive gliosis in 
the central nervous system (Alderson RF 2000, Fryer RH 1997).
Whereas in this study reactive gliosis in PVR retinectomy sections is 
associated with increased expression of NT4, the opposite is observed in 
melanoma affected samples with reduced NT4 expression associated with 
reactive gliosis. These contrasting pictures suggest that glial cell 
hypertrophy is not always associated with increased expression of 
neurotrophins and the cause of gliosis and the underlying complex 
interactions of inflammatory agents may differ in different conditions, 
leading to contrasting results.
The immunohistochemical staining on paraffin embedded sections used in 
this study did not detect BDNF or NT3 in any of the retinas examined. 
These findings do not correlate with previous reports in a variety of 
vertebrate retinas (Das I 1997, Bennett JL 1999, Hallbook F 1996,
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Cellerino A 1997). It may be that the antibodies used in this study did not 
recognise the epitopes expressed in paraffin tissues, or that the method 
used was not sensitive enough. Strong expression of GFAP was observed 
in control melanoma eyes as well as laser treated eyes, but minimal 
expression of these molecules was seen in normal controls. Increased 
levels of this protein has been reported in the Muller cells following laser 
exposure in rabbit eyes (Humphrey MF 1993 and 1997) where GFAP 
immunoreactivity in Muller cells was observed as far as 4-5 mm from the 
laser foci which was much larger than the RPE disrupted area (Humphrey 
MF 1993). Findings presented here suggest that retinal GFAP expression 
is increased in the presence of melanoma and laser treatment did not 
modify this expression. It is of interest that an increased immunoreactivity 
for GFAP has also been observed in retinal explants when exposed to 
choroidal melanoma cells ex vivo (Enzmann v 2000). GFAP may be 
maximally expressed in melanoma eyes and therefore it may not be 
possible to detect a further increase using immunocytochemical 
techniques following laser treatment.
The expression of CD68 was only observed at the site of the laser treated 
retinas and not in the normal or melanoma affected eyes. Immunoreactive 
cells were localised in the laser damaged RPE as well as in the underlying 
choroid. CD68 is a cell surface marker for macrophages and has 
previously been reported to be expressed by cultured RPE cells (Limb GA 
1997, E lnerSG 1992).
Macrophages and leucocyte infiltrates characterise inflammatory 
responses and their presence in the choroid in foci of laser disruption may
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indicate an inflammatory response induced by this treatment. Previous 
studies have shown that the origin of the mononuclear leukocytes that 
accumulate at the site of laser burns is the systemic circulation (Martini B 
1992, Ishikawa Y 1983).
Findings here agree with those previously reported (Nicolai U 1993) where 
RPE cells in specimens obtained from eyes with various ocular diseases 
including intraocular melanoma did not react with antibody to CD68. This 
observation suggests that laser damaged RPE cells and those cultured 
(Limb GA 1997, Cellerino A 1997) (“normal”) may have undergone 
activation, not seen in normal cells in vivo.
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Future directions
Since Muller cells span the entire thickness of the retina, gene delivery to 
these cells is a usefull strategy to provide protection to all retinal cell 
types. It may be possible to stimulate these cells to provide 
neuroprotection given that over expression of BDNF was observed in 
response to PDGF, an important inflammatory factor produced during 
retinal inflammatory conditions such as PVR. The exact role of NT4 in the 
human retina is yet to be determined but it would be of importance to 
investigate the effect of various factors on NT4 production by Muller cells, 
as well as to determine the possible autocrine role of Muller cells given the 
coexpression of BDNF, NT4 and their common receptor TrkB.
Vascular endothelial growth factor (VEGF) expression by Muller cells is 
also of particular interest due to the important role of this angiogenic factor 
in normal retinal vasculature development and in pathological conditions 
such as age related macular degeneration and diabetic retinopathy. Since 
BDNF has been shown to play a role in regulating VEGF production 
(Nakamura K 2006), it would be of interest to investigate the existence of 
autocrine and oparacrine mechanisms that may control physiological 
responses to neuronal injury in retinal disease.
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Conclusion
This study adds to the growing recognition of the importance of Muller 
cells in the maintenance and support of other retinal cell types by 
producing or assisting in trafficking of neurotrophins. NT expression may 
be enhanced, as shown in PVR specimens or diminished as demonstrated 
in melanoma affected eyes and laser induced injury. A substantial 
increase in expression of one NT may lead to reduction of availability of its 
receptor and Muller cells may be involved in internalization and transport 
of NT in the retina.
Functional changes in RPE cells, demonstrated by changes in CD68 
expression and down regulation of the NT4 in the ONL may be 
responsible for some of the changes seen in the retinal function after laser 
induced injury. Alterations in the expression of other neurotrophins and 
their receptors may also play a role in the response of the retina to various 
injuries. Further studies are needed to investigate the role of 
neurotrophins in the pathobiology of wound repair in the retina and 
possible role of NT4 in PVR.
Cheng L et al (2002) have shown that availability of TrK receptors is very 
important if exogenous (or endogenous) NTs are to have their supportive 
effect. There is growing interest in intraocular delivery of various growth 
factors and NTs to promote neuronal survival. Findings of this study show 
increased NT4 staining and reduced TrkB detection in PVR specimens. 
These findings support previous reports and indicate that delivery of NTs 
on their own may not be an adequate strategy for neuronal support.
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Appendix
BDNF gene sequence (Jones KR 1990)
1 ggtgaaagaa agccctaacc agttttctgt cttgtttctg ctttctccct acagttccac 
61 caggtgagaa gagtgatgac catccttttc cttactatgg ttatttcata ctttggttgc 
121 atgaaggctg cccccatgaa agaagcaaac atccgaggac aaggtggctt ggcctaccca 
181 ggtgtgcgga cccatgggac tctggagagc gtgaatgggc ccaaggcagg ttcaagaggc 
241 ttgacatcat tggctgacac tttcgaacac gtgatagaag agctgttgga tgaggaccag 
301 aaagttcggc ccaatgaaga a | H H H H H H i E tacacgtc cagggtgatg 
361 ctcagtagtc aagtgccttt ggagcctcct cttctctttc tgctggagga atacaaaaat 
421 tacctagatg ctgcaaacat gtccatgagg gtccggcgcc actctgaccc tgcccgccga 
481 ggggagctga gcgtgtgtga cagtattagt gagtgggtaa c g g H H ^ H I I B  
541 dgtggaca tgtcgggcgg gacggtcaca gtccttgaaa aggtccctgt atcaaaaggc 
601 caactgaagc aatacttcta cgagaccaag tgcaatccca tgggttacac aaaagaaggc 
661 tgcaggggca tagacaaaag gcattggaac tcccagtgcc gaactaccca gtcgtacgtg 
721 cgggccctta ccatggatag caaaaagaga attggctggc gattcataag gatagacact 
781 tcttgtgtat gtacattgac cattaaaagg ggaagatagt ggatttatgt tgtatagatt 
841 agattatatt gagacaaaaa ttatctattt gtatatatac ataacagggt aaattattca 
901 gttaagaaaa aaataatt
Prim er binding sites are highlighted in red.
130
NT4 gene sequence (ipNY 1992)
1 cttgtcaccc aggtggcagg ggagtggtgc actctctgct cactgcaacc tcggcctcct 
61 gggttcgagt gattctccta cctcagccta ctgagtagct gggattacag gcgtgcagca 
121 ctatgcccgg ttaattttgg tatttttggt agagatgagg tttcaccatg ttgaccagct 
181 gctctggaac tcctgacctc aagtcatcca cctgcctcag cctcccagag tgctgggatt 
241 agaggtgtgg ggcacagtgc ctggcctgta gtagttgaat atttattatt aatctacaag 
301 ttgcgcatta cgcaagccct agatataggg tcccccaaac ttctagaaca agggcttccc 
361 cacaatcctg gcaggcaagc ctcccctggg gttcccaact tctttcccca ctgaagtttt 
421 tacccccttc tctaatccca gcctccctct ttctgtctcc aggtgctccg agagatgctc 
481 cctctcccct catgctccct ccccatcctc ctccttttcc tcctccccag tgtgccaatt 
541 gagtcccaac ccccaccctc aacattgccc ccttttctgg cccctgagtg ggaccttctc 
601 tccccccgag tagtcctgtc taggggtgcc cctgctgggc cccctctgct cttcctgctg 
661 gaggctggggcctttcggga gtcagcaggt gccccggcca accgcagccg gcgtggggtg 
721 B H I H H H I  tcgtcggggt gagctggctg tgtgcgatgc agtcagtggc 
781 tgggtgacag accgccggac cgctgtggac ttgcgtgggc gcgaggtgga ggtgttgggc 
841 gaggtgcctg cagctggcgg cagtcccctc cgccagtact tctttgaaac ccgctgcaag 
901 g c | B H H H H H g c c c g g g g  gcaggtggag ggggctgccg gggagtggac 
961 aggaggcact gggtatctga gtgcaaggcc aagcagtcct atgtgcgggc attgaccgct 
1021 gatgcccagg gccgtgtggg ctggcgatgg attcgaattg acactgcctg cgtctgcaca 
1081 ctcctcagcc ggactggccg ggcctgagac ccatgcccag gaaaataaca gagctggatg 
1141 ctgagagacc tcagggatgg cccagctgat ctaaggaccc cagtttggga actcatcaaa 
1201 taatcacaaa atcacaattc tctgattttg agctcaatct ctgcaggatg ggtgaaacca 
1261 catggggttt tggaggttga ataggagttc tcctggagca acttgagggt aataatgatg 
1321 atgatataat aataatagcc actatttact gagtgtttac tgtttcttat ccctaataca 
1381 taactcctca gatcaactct catg
Prim er binding sites are highlighted in red.
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t-TrkB gene sequence (Shelton d l  1995)
1 ggaaggttta aagaagaagc cgcaaagcgc agggaaggcc tcccggcacg ggtgggggaa 
61 agcggccggt gcagcgcggg gacaggcact cgggctggca ctggctgcta gggatgtcgt 
121 cctggataag gtggcatgga cccgccatgg cgcggctctg gggcttctgc tggctggttg 
181 tgggcttctg gagggccgct ttcgcctgtc ccacgtcctg caaatgcagt gcctctcgga 
241 tctggtgcag cgacccttct cctggcatcg tggcatttcc gagattggag cctaacagtg 
301 tagatcctga gaacatcacc gaaattttca tcgcaaacca gaaaaggtta gaaatcatca 
361 acgaagatga tgttgaagct tatgtgggac tgagaaatct gacaattgtg gattctggat 
421 taaaatttgt ggctcataaa gcatttctga aaaacagcaa cctgcagcac atcaatttta 
481 cccgaaacaa actgacgagt ttgtctagga aacatttccg tcaccttgac ttgtctgaac 
541 tgatcctggt gggcaatcca tttacatgct cctgtgacat tatgtggatc aagactctcc 
601 aagaggctaa atccagtcca gacactcagg atttgtactg cctgaatgaa agcagcaaga 
661 atattcccct ggcaaacctg cagataccca attgtggttt gccatctgca aatctggccg 
721 cacctaacct cactgtggag gaaggaaagt ctatcacatt atcctgtagt gtggcaggtg 
781 atccggttcc taatatgtat tgggatgttg gtaacctggt ttccaaacat atgaatgaaa 
841 caagccacac acagggctcc ttaaggataa ctaacatttc atccgatgac agtgggaagc 
901 agatctcttg tgtggcggaa aatcttgtag gagaagatca agattctgtc aacctcactg 
961 tgcattttgc accaactatc acatttctcg aatctccaac ctcagaccac cactggtgca 
1021 ttccattcac tgtgaaaggc aacccaaaac cagcgcttca gtggttctat aacggggcaa 
1081 tattgaatga gtccaaatac atctgtacta aaatacatgt taccaatcac acggagtacc 
1141 acggctgcct ccagctggat aatcccactc acatgaacaa tggggactac actctaatag 
1201 ccaagaatga gtatgggaag gatgagaaac agatttctgc tcacttcatg ggctggcctg 
1261 gaattgacga tggtgcaaac ccaaattatc ctgatgtaat ttatgaagat tatggaactg 
1321 cagcgaatga catcggggac accacgaaca gaagtaatga aatcccttcc acagacgtca 
1381 c t g a H H H H M H H t c t c g g  tctatgctgt ggtggtgatt gcgtctgtgg 
1441 tgggattttg ccttttggta atgctgtttc tgcttaagtt ggcaagacac tccaagtttg 
1501 gcatgaaag| ttttgttttg tttcata&ga tcccactgga tgggtagctg aaataaagga 
1561 aaagacagag aaaggggctg tggtgcttgt tggttgatgc tgccatgtaa gctggactcc 
1621 tgggactgct gttggcttat cccgggaagt gctgcttatc tggggttttc tggtagatgt 
1681 gggcggtgtt tggaggctgt actatatgaa gcctgcatat actgtgagct gtgattgggg 
1741 aacaccaatg cagaggtaac tctcaggcag ctaagcagca cctcaagaaa acatgttaaa 
1801 ttaatgcttc tcttcttaca gtagttcaaa tacaaaactg aaatgaaatc ccattggatt 
1861 gtacttctct
Red; prim ers produce 166bp product (Labouyrie E 1999)
Yellow; prim ers produce 430bp product (W ordinger R 2000)
Green; sequence identical to full length receptor up to and including
nucleotide 1510
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TrkB gene sequence (Shelton dl 1995)
1 ggaaggttta aagaagaagc cgcaaagcgc agggaaggcc tcccggcacg ggtgggggaa 
61 agcggccggt gcagcgcggg gacaggcact cgggctggca ctggctgcta gggatgtcgt 
121 cctggataag gtggcatgga cccgccatgg cgcggctctg gggcttctgc tggctggttg 
181 tgggcttctg gagggccgct ttcgcctgtc ccacgtcctg caaatgcagt gcctctcgga 
241 tctggtgcag cgacccttct cctggcatcg tggcatttcc gagattggag cctaacagtg 
301 tagatcctga gaacatcacc gaaattttca tcgcaaacca gaaaaggtta gaaatcatca 
361 acgaagatga tgttgaagct tatgtgggac tgagaaatct gacaattgtg gattctggat 
421 taaaatttgt ggctcataaa gcatttctga aaaacagcaa cctgcagcac atcaatttta 
481 cccgaaacaa actgacgagt ttgtctagga aacatttccg tcaccttgac ttgtctgaac 
541 tgatcctggt gggcaatcca tttacatgct cctgtgacat tatgtggatc aagactctcc 
601 aagaggctaa atccagtcca gacactcagg atttgtactg cctgaatgaa agcagcaaga 
661 atattcccct ggcaaacctg cagataccca attgtggttt gccatctgca aatctggccg 
721 cacctaacct cactgtggag gaaggaaagt ctatcacatt atcctgtagt gtggcaggtg 
781 atccggttcc taatatgtat tgggatgttg gtaacctggt ttccaaacat atgaatgaaa 
841 caagccacac acagggctcc ttaaggataa ctaacatttc atccgatgac agtgggaagc 
901 agatctcttg tgtggcggaa aatcttgtag gagaagatca agattctgtc aacctcactg 
961 tgcattttgc accaactatc acatttctcg aatctccaac ctcagaccac cactggtgca 
1021 ttccattcac tgtgaaaggc aacccaaaac cagcgcttca gtggttctat aacggggcaa
1081 tattgaatga gtccaaajac atctgtacta aaat&cajtgt taccaatcac acggagtacc
1141 acggctgcct ccagctggat aatcccactc acatgaacaa tggggactac actctaatag 
1201 ccaagaatga gtatgggaag gatgagaaac agatttctgc tcacttcatg ggctggcctg 
1261 gaattgacg^ggtgcaaac ccaaattatc ctgatgtaat ttatgaagat tatggaactg 
1321 c a H H B B H H H  accacgaaca gaagtaatga aatcccttcc acagacgtca 
1381 ctgataaaac cggtcgggaa catctctcgg tctatgctgt ggtggtgatt gcgtctgtgg 
1441 tgggattttg ccttttggta atgctgtttc tgcttaagtt ggcaagacac tccaagtttg 
1501 gcatgaaagg cccagcctcc gttatcagca atgatgatga ctctgccagc ccactccatc 
1561 acatctccaa tgggagtaac actccatctt cttcggaagg tggcccagat gctgtcatta 
1621 ttggaatgac caagatccct gtcattgaaa atccccagta ctttggcatc accaacagtc 
1681 agctcaagcc agacacattt gttcagcaca tcaagcgaca taacattgtt ctgaaaaggg 
1741 agctaggcga aggagccttt ggaaaagtgt tcctagctga atgctataac ctctgtcctg 
1801 agcaggacaa gatcttggtg gcagtgaaga ccctgaagga tgccagtgac aatgcacgca 
1861 aggacttcca ccgtgaggcc gagctcctga ccaacctcca gcatgagcac atcgtcaagt 
1921 tctatggcgt ctgcgtggag ggcgaccccc tcatcatggt ctttgagtac atgaagcatg 
1981 gggacctcaa caagttcctc agggcacacg gccctgatgc cgtgctgatg gctgagggca 
2041 acccgcccac ggaactgacg cagtcgcaga tgctgcatat agcccagcag atcgccgcgg 
2101 gcatggtcta cctggcgtcc cagcacttcg tgcaccgcga tttggccacc aggaactgcc 
2161 tggtcgggga gaacttgctg gtgaaaatcg gggactttgg gatgtcccgg gacgtgtaca 
2221 gcactgacta ctacagggtc ggtggccaca caatgctgcc cattcgctgg atgcctccag 
2281 agagcatcat gtacaggaaa ttcacgacgg aaagcgacgt ctggagcctg ggggtcgtgt 
2341 tgtgggagat tttcacctat ggcaaacagc cctggtacca gctgtcaaac aatgaggtga 
2401 tagagtgtat cactcagggc cgagtcctgc agcgaccccg cacgtgcccc caggaggtgt 
2461 atgagctgat gctggggtgc tggcagcgag agccccacat gaggaagaac atcaagggca 
2521 tccataccct ccttcagaac ttggccaagg catctccggt ctacctggac attctaggct 
2581 agggcccttt tccccagacc gatccttccc aacgtactcc tcagacgggc tgagaggatg 
2641 aacatctttt aactgccgct ggaggccacc aagctgctct ccttcactct gacagtatta 
2701 acatcaaaga ctccgagaag ctctcgaggg aagcagtgtg tacttcttca tccatagaca 
2761 cagtattgac ttctttttgg cattatctct ttctctcttt ccatctccct tggttgttcc
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2821 tttttctttt tttaaatttt ctttttcttc ttttttttcg tcttccctgc ttcacgattc 
2881 ttaccctttc ttttgaatca atctggcttc tgcattacta ttaactctgc atagacaaag 
2941 gccttaacaa acgtaatttg ttatatcagc agacactcca gtttgcccac cacaactaac 
3001 aatgccttgt tgtattcctg cctttgatgt ggatgaaaaa aagggaaaac aaatatttca 
3061 cttaaacttt gtcacttctg ctgtacagat atcgagagtt tctatggatt cacttctatt 
3121 tatttattat tattactgtt cttattgttt ttggatggct taagcctgtg tataaaaaaa 
3181 aaaaaaaatc taga
Extra cellular domain primers position 1098-1117 (highlighted in red)
Kinetic domain primers position 2035-2054 (highlighted in yellow)
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GAPDH gene sequence (Strausberg r 2002)
1 cagtcagccg catcttcttt tgcgtcgcca gccgagccac atcgctgaga caccatgggg 
61 aaggtgaagg tcggagtcaa cggatttggt cgtattgggc gcctggtcac cagggctgct 
121 tttaactctg gtaaagtgga tattgttgcc atcaatgacc ccttcattga cctcaactac 
181 atggtttaca tgttccaata tgattccacc catggcaaat tccatggcac cgtcaaggct 
241 gagaacggga agcttgtcat caatggaaat cccatcacca tcttccagga gcgagatccc 
301 tccaaaatca agtggggcga tgctggcgct gagtacgtcg tggagtccac tggcgtcttc 
361 accaccatgg agaaggctgg ggctcatttg caggggggag ccaaaagggt catcatctct 
421 gccccctctg ctgatgcccc catgttcgtc atgggtgtga accatgagaa gtatgacaac 
481 agcctcaaga tcatcagcaa tgcctcctgc accaccaact gcttagcacc cctggccaag 
541 gtcatccatg acaactttgg tatcgtggaa ggactcatga ccacagtcca tgccatcact 
601 gccacccaga agactgtgga tggcccctcc gggaaactgt ggcgtgatgg ccgcggggct 
661 ctccagaaca tcatccctgc ctctactggc gctgccaagg ctgtgggcaa ggtcatccct 
721 gagctgaacg ggaagctcac tggcatggcc ttccgtgtcc ccactgccaa cgtgtcagt| 
781 ■ ■ ■ ■ ■ ■ ■ ■ a a a a c x t  gccaaatatg atgacatcaa gaaggtggtg 
841 aagcaggcgt cggagggccc cctcaagggc atcctgggct acactgagca ccaggtggtc 
901 tcctctgact tcaacagcga cacccactcc tccacctttg acgctggggc tggcattgcc 
961 ctcaacgacc actttgtcaa gctcatttcc tggtatgaca acgaatttgg ctacagcaac 
1021 agggtggtgg acctcatggc ccacatggcc tccaaggagt aagacccctg gaccaccagc 
1081 cccagcaaga gcacaagagg aagagagaga ccctcactgc tggggagtcc ctgccacact 
1141 cagtccccca ccacactgaa tctcccctcc tcacagttgc catgtagacc ccttgaagag 
1201 gggaggggcc tagggagccg caccttgtca tgtaccatca ataaagtacc ctgtgctcaa 
1261 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa a
Prim er binding sites are highlighted in red.
135
Supporting publications
Peer review publication
Ghazi-Nouri SM, Assi A, Limb GA, Scott RA, von Bussmann K, Humphrey 
I et al. Laser photocoagulation alters the pattern of staining for 
neurotrophin-4, GFAP, and CD68 in human retina. Br.J.Ophthalmol. 
2003;87:488-92.
Published abstracts
Ghazi-Nouri SM, Charteris DG, Moss SE, Limb GA. Upregulation of NT4 
in human retina from eyes with proliferative vitreoretinopathy. Ophthalmic 
research 2003;35 S1(03):267.
Ghazi-Nouri SM, Charteris DG, Moss SE, Limb GA. Production of brain 
derived neurotrophic factor by human Muller cells and its uprtegulation by 
platelet derived growth factor. ARVO 2003 abstract 2244.
Ghazi-Nouri SM, Charteris DG, Moss SE, Limb GA. Expression of NT4, 
BDNF and truncated TrKB by Human Muller cells. Ophthalmic Research 
2002;34 S1(2):123.
Ghazi-Nouri SM, Charteris DG, Moss SE, Limb GA. Expression of NT4 
and TrkB by human Muller cells. ARVO 2002 abstract 666.
136
References
The classification of retinal detachment with proliferative 
vitreoretinopathy. Ophthalmology 1983;90:121-5.
Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST et al. 
Vascular endothelial growth factor in ocular fluid of patients with diabetic 
retinopathy and other retinal disorders. N.Engl.J.Med. 1994;331:1480-7.
Aiello LP, Northrup JM, Keyt BA, Takagi H, Iwamoto MA. Hypoxic 
regulation of vascular endothelial growth factor in retinal cells.
Arch. Ophthalmol. 1995;113:1538-44.
Alderson RF, Curtis R, Alterman AL, Lindsay RM, DiStefano PS. 
Truncated TrkB mediates the endocytosis and release of BDNF and 
neurotrophin-4/5 by rat astrocytes and schwann cells in vitro. Brain Res. 
2000;871:210-22.
Amin RH, Frank RN, Kennedy A, Eliott D, Puklin JE, Abrams GW. 
Vascular endothelial growth factor is present in glial cells of the retina and 
optic nerve of human subjects with nonproliferative diabetic retinopathy. 
Invest Ophthalmol. Vis.Sci. 1997;38:36-47.
Asaria RH, Charteris DG. Proliferative vitreoretinopathy: developments in 
pathogenesis and treatment. Compr.Ophthalmol.Update. 2006;7:179-85.
137
Ashwell KW, Hollander H, Streit W, Stone J. The appearance and 
distribution of microglia in the developing retina of the rat. Vis.Neurosci. 
1989;2:437-48.
Avwenagha O, Bird MM, Lieberman AR, Yan Q, Campbell G. Patterns of 
expression of brain-derived neurotrophic factor and tyrosine kinase B 
mRNAs and distribution and ultrastructural localization of their proteins in 
the visual pathway of the adult rat. Neuroscience 2006;140:913-28.
Aymerich MS, Alberdi EM, Martinez A, Becerra SP. Evidence for pigment 
epithelium-derived factor receptors in the neural retina. Invest 
Ophthalmol.Vis.Sci. 2001 ;42:3287-93.
Banks RE, Forbes MA, Kinsey SE, Stanley A, Ingham E, Walters C et al. 
Release of the angiogenic cytokine vascular endothelial growth factor 
(VEGF) from platelets: significance for VEGF measurements and cancer 
biology. Br.J.Cancer 1998;77:956-64.
Barakat-Walter I. Brain-derived neurotrophic factor-like immunoreactivity is 
localized mainly in small sensory neurons of rat dorsal root ganglia. 
J.Neurosci. Methods 1996;68:281 -8.
Behzadian MA, Wang XL, Shabrawey M, Caldwell RB. Effects of hypoxia 
on glial cell expression of angiogenesis-regulating factors VEGF and TGF- 
beta. Glia 1998;24:216-25.
138
Behzadian MA, Wang XL, Windsor LJ, Ghaly N, Caldwell RB. TGF-beta 
increases retinal endothelial cell permeability by increasing MMP-9: 
possible role of glial cells in endothelial barrier function. Invest 
Ophthalmol. Vis.Sci. 2001 ;42:853-9.
Bennett JL, Zeiler SR, Jones KR. Patterned expression of BDNF and NT-3 
in the retina and anterior segment of the developing mammalian eye. 
Invest Ophthalmol Vis.Sci. 1999;40:2996-3005.
Berka JL, Stubbs AJ, Wang DZ, DiNicolantonio R, Alcorn D, Campbell DJ 
et al. Renin-containing Muller cells of the retina display endocrine 
features. Invest Ophthalmol. Vis.Sci. 1995;36 :1450-8.
Berkemeier LR, Winslow JW, Kaplan DR, Nikolics K, Goeddel DV, 
Rosenthal A. Neurotrophin-5: a novel neurotrophic factor that activates trk 
and trkB. Neuron 1991;7:857-66.
Biffo S, Offenhauser N, Carter BD, Barde YA. Selective binding and 
internalisation by truncated receptors restrict the availability of BDNF 
during development. Development 1995;121:2461-70.
Bignami A, Dahl D. The radial glia of Muller in the rat retina and their 
response to injury. An immunofluorescence study with antibodies to the 
glial fibrillary acidic (GFA) protein. Exp.Eye Res. 1979;28:63-9.
139
Bignami A, Dahl D. The radial glia of Muller in the rat retina and their 
response to injury. An immunofluorescence study with antibodies to the 
glial fibrillary acidic (GFA) protein. Exp.Eye Res. 1979;28:63-9.
Boehm BO, Lang G, Volpert O, Jehle PM, Kurkhaus A, Rosinger S et al. 
Low content of the natural ocular anti-angiogenic agent pigment 
epithelium-derived factor (PEDF) in aqueous humor predicts progression 
of diabetic retinopathy. Diabetologia 2003;46:394-400.
Bok D, Ong DE, Chytil F. Immunocytochemical localization of cellular 
retinol binding protein in the rat retina. Invest Ophthalmol Vis.Sci. 
1984;25:877-83.
Bothwell M. Functional interactions of neurotrophins and neurotrophin 
receptors. Annu.Rev.Neurosci. 1995;18:223-53.
Bovolenta P, Frade JM, Marti E, Rodriguez-Pena MA, Barde YA, 
Rodriguez-Tebar A. Neurotrophin-3 antibodies disrupt the normal 
development of the chick retina. J.Neurosci. 1996;16:4402-10.
Brady R, Zaidi SI, Mayer C, Katz DM. BDNF is a target-derived survival 
factor for arterial baroreceptor and chemoafferent primary sensory 
neurons. J.Neurosci. 1999;19:2131-42.
140
Brew H, Gray PT, Mobbs P, Attwell D. Endfeet of retinal glial cells have 
higher densities of ion channels that mediate K+ buffering. Nature 
1986;324:466-8.
Bunt-Milam AH, Saari JC. Immunocytochemical localization of two 
retinoid-binding proteins in vertebrate retina. J.Cell Biol. 1983;97:703-12.
Butte MJ, Hwang PK, Mobley WC, Fletterick RJ. Crystal structure of 
neurotrophin-3 homodimer shows distinct regions are used to bind its 
receptors. Biochemistry 1998;37:16846-52.
Cartwright M, Mikheev AM, Heinrich G. Expression of neurotrophin genes 
in human fibroblasts: differential regulation of the brain-derived 
neurotrophic factor gene. Int.J.Dev.Neurosci. 1994;12:685-93.
Castilla MA, Arroyo MV, Aceituno E, Aragoncillo P, Gonzalez-Pacheco 
FR, Texeiro E et al. Disruption of cadherin-related junctions triggers 
autocrine expression of vascular endothelial growth factor in bovine aortic 
endothelial cells : effects on cell proliferation and death resistance. 
Circ.Res. 1999;85:1132-8.
Cellerino A, Kohler K. Brain-derived neurotrophic factor/neurotrophin-4 
receptor TrkB is localized on ganglion cells and dopaminergic amacrine 
cells in the vertebrate retina. J.Comp Neurol. 1997;386:149-60.
141
Chan-Ling T. In: Osborne N, Chader G, eds. Progress in Retinal and Eye 
Research. Elsevier, 1994: 357-89.
Chao MV. The p75 neurotrophin receptor. J.Neurobiol. 1994;25:1373-85.
Chen L, Yang P, Kijlstra A. Distribution, markers, and functions of retinal 
microglia. Ocul.Immunol.Inflamm. 2002; 10:27-39.
Cheng L, Sapieha P, Kittlerova P, Hauswirth WW, Di Polo A. TrkB gene 
transfer protects retinal ganglion cells from axotomy-induced death in vivo. 
J.Neurosci. 2002;22:3977-86.
Chong NH, Alexander RA, Waters L, Barnett KC, Bird AC, Luthert PJ. 
Repeated injections of a ciliary neurotrophic factor analogue leading to 
long-term photoreceptor survival in hereditary retinal degeneration. Invest 
Ophthalmol Vis.Sci. 1999;40:1298-305.
Clarke DB, Bray GM, Aguayo AJ. Prolonged administration of NT-4/5 fails 
to rescue most axotomized retinal ganglion cells in adult rats. Vision Res. 
1998;38:1517-24.
Condon GP, Brownstein S, Wang NS, Kearns JA, Ewing CC. Congenital 
hereditary (juvenile X-linked) retinoschisis. Histopathologic and 
ultrastructural findings in three eyes. Arch Ophthalmol 1986;104:576-83.
142
Cunningham ET, Jr., Adamis AP, Altaweel M, Aiello LP, Bressler NM, 
D'Amico DJ et al. A phase II randomized double-masked trial of 
pegaptanib, an anti-vascular endothelial growth factor aptamer, for 
diabetic macular edema. Ophthalmology 2005;112:1747-57.
DAmico DJ, Masonson HN, Patel M, Adamis AP, Cunningham ET, Jr., 
Guyer DR et al. Pegaptanib sodium for neovascular age-related macular 
degeneration: two-year safety results of the two prospective, multicenter, 
controlled clinical trials. Ophthalmology 2006;113:992-1001.
Das I, Hempstead BL, MacLeish PR, Sparrow JR. Immunohistochemical 
analysis of the neurotrophins BDNF and NT-3 and their receptors trk B, trk 
C, and p75 in the developing chick retina. Vis.Neurosci. 1997;14:835-42.
de Jong PT, Zrenner E, van Meel GJ, Keunen JE, van Norren D. Mizuo 
phenomenon in X-linked retinoschisis. Pathogenesis of the Mizuo 
phenomenon. Arch.Ophthalmol. 1991 ;109:1104-8.
de la Chapelle A ATFH. In: Wright A JB, ed. Molecular Genetics of 
Inherited Eye Disorders. Harwood Academic, 1994: 339-57.
Dechant G, Barde YA. Signalling through the neurotrophin receptor 
p75NTR. Curr.Opin.Neurobiol. 1997;7:413-8.
Di Polo A, Aigner LJ, Dunn RJ, Bray GM, Aguayo AJ. Prolonged delivery 
of brain-derived neurotrophic factor by adenovirus-infected Muller cells
143
temporarily rescues injured retinal ganglion cells.
Proc.Natl.Acad.Sci. U.S. A 1998;95:3978-83.
Distler C, Dreher Z. Glia cells of the monkey retina—II. Muller cells. Vision 
Res. 1996;36:2381-94.
Dowling JE. In: The retina: an approachable part of the brain. Belknap 
press, Cambridge, MA, 1987: 282.
Dreher Z, Wegner M, Stone J. Muller cell endfeet at the inner surface of 
the retina: light microscopy. Vis.Neurosci. 1988;1:169-80.
Dreher Z, Robinson SR, Distler C. Muller cells in vascular and avascular 
retinae: a survey of seven mammals. J.Comp Neurol. 1992;323:59-80.
Dubois-Dauphin M, Poitry-Yamate C, de Bilbao F, Julliard AK, Jourdan F, 
Donati G. Early postnatal Muller cell death leads to retinal but not optic 
nerve degeneration in NSE-Hu-Bcl-2 transgenic mice. Neuroscience 
2000;95:9-21.
Duh EJ, Yang HS, Suzuma I, Miyagi M, Youngman E, Mori K et al. 
Pigment epithelium-derived factor suppresses ischemia-induced retinal 
neovascularization and VEGF-induced migration and growth. Invest 
Ophthalmol. Vis.Sci. 2002;43:821-9.
144
Dvorak HF, Nagy JA, Feng D, Brown LF, Dvorak AM. Vascular 
permeability factor/vascular endothelial growth factor and the significance 
of microvascular hyperpermeability in angiogenesis.
Curr. Top.Microbiol.Immunol. 1999;237:97-132.
Eichler W , Kuhrt H, Hoffmann S, Wiedemann P, Reichenbach A. VEGF 
release by retinal glia depends on both oxygen and glucose supply. 
Neuroreport 2000; 11:3533-7.
Eichler W , Yafai Y, Wiedemann P, Reichenbach A. Angiogenesis-related 
factors derived from retinal glial (Muller) cells in hypoxia. Neuroreport 
2004;15:1633-7.
Eichler W, Yafai Y, Keller T, Wiedemann P, Reichenbach A. PEDF 
derived from glial Muller cells: a possible regulator of retinal angiogenesis. 
Exp.Cell Res. 2004;299:68-78.
Eide FF, Vining ER, Eide BL, Zang K, Wang XY, Reichardt LF. Naturally 
occurring truncated trkB receptors have dominant inhibitory effects on 
brain-derived neurotrophic factor signaling. J.Neurosci. 1996;16:3123-9.
Ekstrom P, Sanyal S, Narfstrom K, Chader GJ, van Veen T. Accumulation 
of glial fibrillary acidic protein in Muller radial glia during retinal 
degeneration, invest Ophthalmol. Vis.Sci. 1988;29:1363-71.
145
Elner SG, Elner VM, Nielsen JC, Torczynski E, Yu R, Franklin WA. CD68 
antigen expression by human retinal pigment epithelial cells. Exp.Eye 
Res. 1992;55:21-8.
Enzmann V, Germer A, Francke M, Kohen L, Wiedemann P, Reichenbach 
A. Alterations of sensory retinal explants exposed to choroidal melanoma 
cells ex vivo. Graefes Arch Clin.Exp.Ophthalmol 2000;238:985-92.
Erickson PA, Fisher SK, Guerin CJ, Anderson DH, Kaska DD. Glial 
fibrillary acidic protein increases in Muller cells after retinal detachment. 
Exp.Eye Res. 1987;44:37-48.
Ernfors P, Ibanez CF, Ebendal T, Olson L, Persson H. Molecular cloning 
and neurotrophic activities of a protein with structural similarities to nerve 
growth factor: developmental and topographical expression in the brain. 
Proc. Natl. Acad. Sci. U. S. A 1990;87:5454-8.
Ernfors P, Merlio JP, Persson H. Cells Expressing mRNAfor 
Neurotrophins and their Receptors During Embryonic Rat Development. 
Eur. J.Neurosci. 1992;4:1140-58.
Fandl JP, Tobkes NJ, McDonald NQ, Hendrickson WA, Ryan TE, Nigam S 
et al. Characterization and crystallization of recombinant human 
neurotrophin-4. J.Biol.Chem. 1994;269:755-9.
146
Farinas I, Yoshida CK, Backus C, Reichardt LF. Lack of neurotrophin-3 
results in death of spinal sensory neurons and premature differentiation of 
their precursors. Neuron 1996;17:1065-78.
Fayard B, Loeffler S, Weis J, Vogelin E, Kruttgen A. The secreted brain- 
derived neurotrophic factor precursor pro-BDNF binds to TrkB and 
p75NTR but not to TrkA or TrkC. J.Neurosci.Res. 2005;80:18-28.
Fernando NH, Hurwitz HI. Inhibition of vascular endothelial growth factor 
in the treatment of colorectal cancer. Semin.Oncol. 2003;30:39-50.
Fine BS, Brucker AJ. Macular edema and cystoid macular edema.
Am.J. Ophthalmol. 1981;92:466-81.
Fischer W, Wictorin K, Bjorklund A, Williams LR, Varon S, Gage FH. 
Amelioration of cholinergic neuron atrophy and spatial memory impairment 
in aged rats by nerve growth factor. Nature 1987;329:65-8.
Fisher S, Anderson D. In: Ryan S, ed. Retina. St. Louis: Mosby, CV, 1994: 
2035-61.
Frank L, Ventimiglia R, Anderson K, Lindsay RM, Rudge JS. BDNF down- 
regulates neurotrophin responsiveness, TrkB protein and TrkB mRNA 
levels in cultured rat hippocampal neurons. Eur.J.Neurosci. 1996;8:1220- 
30.
147
Frank RN, Amin RH, Eliott D, Puklin JE, Abrams GW. Basic fibroblast 
growth factor and vascular endothelial growth factor are present in 
epiretinal and choroidal neovascular membranes. Am.J.Ophthalmol. 
1996;122:393-403.
Fryer RH, Kaplan DR, Kromer LF. Truncated trkB receptors on 
nonneuronal cells inhibit BDNF-induced neurite outgrowth in vitro.
Exp. Neurol. 1997;148:616-27.
Gao H, Qiao X, Hefti F, Hollyfield JG, Knusel B. Elevated mRNA 
expression of brain-derived neurotrophic factor in retinal ganglion cell 
layer after optic nerve injury. Invest Ophthalmol Vis.Sci. 1997;38:1840-7.
Garcia M, Forster V, Hicks D, Vecino E. Effects of mullerglia on cell 
survival and neuritogenesis in adult porcine retina in vitro. Invest 
Ophthalmol Vis.Sci. 2002;43:3735-43.
Garcia M, Forster V, Hicks D, Vecino E. In vivo expression of 
neurotrophins and neurotrophin receptors is conserved in adult porcine 
retina in vitro. Invest Ophthalmol Vis.Sci. 2003;44:4532-41.
Gass JD, Anderson DR, Davis EB. A clinical, fluorescein angiographic, 
and electron microscopic correlation of cystoid macular edema.
Am.J.Ophthalmol. 1985;100:82-6.
148
Gass JD. Muller cell cone, an overlooked part of the anatomy of the fovea 
centralis: hypotheses concerning its role in the pathogenesis of macular 
hole and foveomacualr retinoschisis. Arch.Ophthalmol. 1999;117:821-3.
Gaur VP, Eldred W , Sarthy PV. Distribution of Muller cells in the turtle 
retina: an immunocytochemical study. J.Neurocytol. 1988;17:683-92.
Ghazi-Nouri SM, Assi A, Limb GA, Scott RA, von Bussmann K, Humphrey 
I et al. Laser photocoagulation alters the pattern of staining for 
neurotrophin-4, GFAP, and CD68 in human retina. Br.J.Ophthalmol. 
2003;87:488-92.
Gillespie DC, Crair MC, Stryker MP. Neurotrophin-4/5 alters responses 
and blocks the effect of monocular deprivation in cat visual cortex during 
the critical period. J.Neurosci. 2000;20:9174-86.
Glebova NO, Ginty DD. Growth and survival signals controlling 
sympathetic nervous system development. Annu.Rev.Neurosci. 
2005;28:191-222.
Gordon MS, Margolin K, Talpaz M, Sledge GW, Jr., Holmgren E,
Benjamin R et al. Phase I safety and pharmacokinetic study of 
recombinant human anti-vascular endothelial growth factor in patients with 
advanced cancer. J.Clin.Oncol. 2001;19:843-50.
149
Goureau O, Regnier-Ricard F, Courtois Y. Requirement for nitric oxide in 
retinal neuronal cell death induced by activated Muller glial cells. 
J.Neurochem. 1999;72:2506-15.
Goureau O, Rhee KD, Yang XJ. Ciliary neurotrophic factor promotes 
muller glia differentiation from the postnatal retinal progenitor pool. 
Dev.Neurosci. 2004;26:359-70.
Gragoudas ES, Adamis AP, Cunningham ET, Jr., Feinsod M, Guyer DR. 
Pegaptanib for neovascular age-related macular degeneration. 
N.Engl.J.Med. 2004;351:2805-16.
Guerin CJ, Wolfshagen RW, Eifrig DE, Anderson DH. 
Immunocytochemical identification of Muller's glia as a component of 
human epiretinal membranes. Invest Ophthalmol Vis.Sci. 1990;31:1483-
91.
Guidry C. Tractional force generation by porcine Muller cells. 
Development and differential stimulation by growth factors. Invest 
Ophthalmol Vis.Sci. 1997;38:456-68.
Guyer DR, Green WR, de Bustros S, Fine SL. Histopathologic features of 
idiopathic macular holes and cysts. Retina 2005;25:1045-51.
Haas J. Ueber das zusammenvorkommen von veraenderungen der retina 
und choroidea. Arch Augenheilkd 1898;37:343-8.
150
Haber M, Cao Z, Panjwani N, Bedenice D, Li WW , Provost PJ. Effects of 
growth factors (EGF, PDGF-BB and TGF-beta 1) on cultured equine 
epithelial cells and keratocytes: implications for wound healing. 
Vet.Ophthalmol. 2003;6:211-7.
Hallbook F, Ibanez CF, Persson H. Evolutionary studies of the nerve 
growth factor family reveal a novel member abundantly expressed in 
Xenopus ovary. Neuron 1991;6:845-58.
Hallbook F, Backstrom A, Kullander K, Ebendal T, Carri NG. Expression of 
neurotrophins and trk receptors in the avian retina. J.Comp Neurol. 
1996;364:664-76.
Hammes HP, Federoff HJ, Brownlee M. Nerve growth factor prevents both 
neuroretinal programmed cell death and capillary pathology in 
experimental diabetes. Mol.Med. 1995;1:527-34.
Harada T, Harada C, Nakayama N, Okuyama S, Yoshida K, Kohsaka S et 
al. Modification of glial-neuronal cell interactions prevents photoreceptor 
apoptosis during light-induced retinal degeneration. Neuron 2000;26:533- 
41.
Harris GS, Yeung J. Maculopathy of sex-linked juvenile retinoschisis.
Can. J. Ophthalmol 1976;11:1 -10.
151
Hefti F, Weiner WJ. Nerve growth factor and Alzheimer's disease.
Ann.Neurol. 1986;20:275-81.
Heier JS, Boyer DS, Ciulla TA, Ferrone PJ, Jumper JM, Gentile RC et al. 
Ranibizumab combined with verteporfin photodynamic therapy in 
neovascular age-related macular degeneration: year 1 results of the 
FOCUS Study. Arch.Ophthalmol. 2006;124:1532-42.
Henderson CE. Role of neurotrophic factors in neuronal development. 
Curr.Opin.Neurobiol. 1996;6:64-70.
Hirsch S, Labes M, Bahr M. Changes in BDNF and neurotrophin receptor 
expression in degenerating and regenerating rat retinal ganglion cells. 
Restor.Neurol.Neurosci. 2000;17:125-34.
Hiscott PS, Grierson I, Trombetta CJ, Rahi AH, Marshall J, McLeod D. 
Retinal and epiretinal glia--an immunohistochemical study.
Br.J.Ophthalmol 1984;68:698-707.
Hollander H, Makarov F, Dreher Z, van Driel D, Chan-Ling TL, Stone J. 
Structure of the macroglia of the retina: sharing and division of labour 
between astrocytes and Muller cells. J.Comp Neurol. 1991;313:587-603.
Honjo M, Tanihara H, Kido N, Inatani M, Okazaki K, Honda Y. Expression 
of ciliary neurotrophic factor activated by retinal Muller cells in eyes with. 
Invest Ophthalmol Vis.Sci. 2000;41:552-60.
152
Hotta Y, Fujiki K, Hayakawa M, Ohta T, Fujimaki T, Tamaki K et al. 
Japanese juvenile retinoschisis is caused by mutations of the XLRS1 
gene. Hum .Genet 1998;103:142-4.
Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW. The 
vascular endothelial growth factor family: identification of a fourth 
molecular species and characterization of alternative splicing of RNA. 
Mol.Endocrinol. 1991;5:1806-14.
Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW. The 
vascular endothelial growth factor family: identification of a fourth 
molecular species and characterization of alternative splicing of RNA. 
MotEndocrinol. 1991;5:1806-14.
Huang EJ, Wilkinson GA, Farinas I, Backus C, Zang K, Wong SL et al. 
Expression of Trk receptors in the developing mouse trigeminal ganglion: 
in vivo evidence for NT-3 activation of TrkA and TrkB in addition to TrkC. 
Development 1999;126:2191-203.
Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development 
and function. Annu.Rev.Neurosci. 2001;24:677-736.
Hume DA, Perry VH, Gordon S. Immunohistochemical localization of a 
macrophage-specific antigen in developing mouse retina: phagocytosis of 
dying neurons and differentiation of microglial cells to form a regular array 
in the plexiform layers. J.Cell Biol. 1983;97:253-7.
153
Humphrey MF, Constable I J, Chu Y, Wiffen S. A quantitative study of the 
lateral spread of Muller cell responses to retinal lesions in the rabbit.
J.Comp Neurol. 1993;334:545-58.
Humphrey MF, Chu Y, Mann K, Rakoczy P. Retinal GFAP and bFGF 
expression after multiple argon laser photocoagulation injuries assessed 
by both immunoreactivity and mRNA levels. Exp.Eye Res. 1997; 64:361-9.
Hyde JC, Robinson N. Localisation of sites of GABA catabolism in the rat 
retina. Nature 1974;248:432-3.
Ip NY, Ibanez CF, Nye SH, McClain J, Jones PF, Gies DR et al. 
Mammalian neurotrophin-4: structure, chromosomal localization, tissue 
distribution, and receptor specificity. Proc.Natl.Acad.Sci.U.S.A 
1992;89:3060-4.
Ishii M, Horio Y, Tada Y, Hibino H, Inanobe A, Ito M et al. Expression and 
clustered distribution of an inwardly rectifying potassium channel, KAB- 
2/Kir4.1, on mammalian retinal Muller cell membrane: their regulation by 
insulin and laminin signals. J.Neurosci. 1997;17:7725-35.
Ishikawa Y, Momoeda S, Yoshitomi F. Origin of macrophage in 
photocoagulated rabbit retina. Jpn.J.Ophthalmol 1983;27:138-48.
154
Jelsma TN, Friedman HH, Berkelaar M, Bray GM, Aguayo AJ. Different 
forms of the neurotrophin receptor trkB mRNA predominate in rat retina 
and optic nerve. J.Neurobiol. 1993;24:1207-14.
Jingjing L, Xue Y, Agarwal N, Roque RS. Human Muller cells express 
VEGF183, a novel spliced variant of vascular endothelial growth factor. 
Invest Ophthalmol. Vis.Sci. 1999;40:752-9.
Kafitz KW, Rose CR, Thoenen H, Konnerth A. Neurotrophin-evoked rapid 
excitation through TrkB receptors. Nature 1999;401:918-21.
Kaplan DR, Stephens RM. Neurotrophin signal transduction by the Trk 
receptor. J.Neurobiol. 1994;25:1404-17.
Kaplan DR, Miller FD. Neurotrophin signal transduction in the nervous 
system. Curr.Opin.Neurobiol. 2000;10:381-91.
Karwoski CJ, Lu HK, Newman EA. Spatial buffering of light-evoked 
potassium increases by retinal Muller (glial) cells. Science 1989;244:578- 
80.
Kellner U, Kraus H, Heimann H, Helbig H, Bornfeld N, Foerster MH. 
Electrophysiological evaluation of visual loss in Muller cell sheen 
dystrophy. Br.J.Ophthalmol. 1998;82:650-4.
155
Kishino A, Ishige Y, Tatsuno T, Nakayama C, Noguchi H. BDNF prevents 
and reverses adult rat motor neuron degeneration and induces axonal 
outgrowth. Exp.Neurol. 1997;144:273-86.
Klein R, Conway D, Parada LF, Barbacid M. The trkB tyrosine protein 
kinase gene codes for a second neurogenic receptor that lacks the 
catalytic kinase domain. Cell 1990;61:647-56.
Klein R, Nanduri V, Jing SA, Lamballe F, Tapley P, Bryant S et al. The 
trkB tyrosine protein kinase is a receptor for brain-derived neurotrophic 
factor and neurotrophin-3. Cell 1991;66:395-403.
Klein R, Lamballe F, Bryant S, Barbacid M. The trkB tyrosine protein 
kinase is a receptor for neurotrophin-4. Neuron 1992;8:947-56.
Knusel B, Gao H, Okazaki T, Yoshida T, Mori N, Hefti F et al. Ligand- 
induced down-regulation of Trk messenger RNA, protein and tyrosine 
phosphorylation in rat cortical neurons. Neuroscience 1997;78:851-62.
Kobayashi M, Kuroiwa T, Shimokawa R, Okeda R, Tokoro T. Nitric oxide 
synthase expression in ischemic rat retinas. Jpn.J.Ophthalmol 
2000;44:235-44.
Kobayashi NR, Fan DP, Giehl KM, Bedard AM, Wiegand SJ, Tetzlaff W. 
BDNF and NT-4/5 prevent atrophy of rat rubrospinal neurons after cervical
156
axotomy, stimulate GAP-43 and Talphal-tubulin mRNA expression, and 
promote axonal regeneration. J.Neurosci. 1997;17:9583-95.
Koeberle PD, Ball AK. Nitric oxide synthase inhibition delays axonal 
degeneration and promotes the survival of axotomized retinal ganglion 
cells. Exp.Neurol. 1999;158:366-81.
Kono T, Kohno T, Inomata H. Epiretinal membrane formation. Light and 
electron microscopic study in an experimental rabbit model. Arch 
Ophthalmol 1995;113:359-63.
Korsching S. The neurotrophic factor concept: a reexamination. 
J.Neurosci. 1993;13:2739-48.
Korte GE, Hageman GS, Pratt DV, Glusman S, Marko M, Ophir A. 
Changes in Muller cell plasma membrane specializations during subretinal 
scar formation in the rabbit. Exp.Eye Res. 1992;55:155-62.
la Cour M, Friis J. Macular holes: classification, epidemiology, natural 
history and treatment. Acta Ophthalmol.Scand. 2002;80:579-87.
Labouyrie E, Dubus P, Groppi A, Mahon FX, Ferrer J, Parrens M et al. 
Expression of neurotrophins and their receptors in human bone marrow. 
Am.J.Pathol. 1999;154:405-15.
157
Lamballe F, Klein R, Barbacid M. trkC, a new member of the trk family of 
tyrosine protein kinases, is a receptor for neurotrophin-3. Cell 
1991;66:967-79.
Lambert W , Agarwal R, Howe W, Clark AF, Wordinger RJ. Neurotrophin 
and neurotrophin receptor expression by cells of the human lamina 
cribrosa. Invest Ophthalmol Vis.Sci. 2001;42:2315-23.
LaVail MM, Yasumura D, Matthes MT, Lau-Villacorta C, Unoki K, Sung 
CH et al. Protection of mouse photoreceptors by survival factors in retinal 
degenerations. Invest Ophthalmol. Vis.Sci. 1998;39:592-602.
Lee R, Kermani P, Teng KK, Hempstead BL. Regulation of cell survival by 
secreted proneurotrophins. Science 2001;294:1945-8.
Leibrock J, Lottspeich F, Hohn A, Hofer M, Hengerer B, Masiakowski P et 
al. Molecular cloning and expression of brain-derived neurotrophic factor. 
Nature 1989;341:149-52.
Levi-Montalcini R. The nerve growth factor 35 years later. Science 
1987;237:1154-62.
Lewis GP, Erickson PA, Guerin CJ, Anderson DH, Fisher SK. Changes in 
the expression of specific Muller cell proteins during long-term retinal 
detachment. Exp.Eye Res. 1989;49:93-111.
158
Lewis GP, Guerin CJ, Anderson DH, Matsumoto B, Fisher SK. Rapid 
changes in the expression of glial cell proteins caused by experimental 
retinal detachment. Am.J.Ophthalmol. 1994;118:368-76.
Lewis GP, Linberg KA, GellerSF, Guerin CJ, Fisher SK. Effects of the 
neurotrophin brain-derived neurotrophic factor in an experimental model of 
retinal detachment. Invest Ophthalmol. Vis.Sci. 1999;40:1530-44.
Lewis GP, Charteris DG, Sethi CS, Fisher SK. Animal models of retinal 
detachment and reattachment: identifying cellular events that may affect 
visual recovery. Eye 2002;16:375-87.
Liebl DJ, Huang W, Young W, Parada LF. Regulation of Trk receptors 
following contusion of the rat spinal cord. Exp.Neurol. 2001;167:15-26.
Liepinsh E, Nag LL, Otting G, Ibanez CF. NMR structure of the death 
domain of the p75 neurotrophin receptor. EMBOJ. 1997;16:4999-5005.
Limb GA, Cole CJ, Earley O, Hollifield RD, Russell W, Stanford MR. 
Expression of hematopoietic cell markers by retinal pigment epithelial 
cells. Curr.Eye Res. 1997;16:985-91.
Limb GA, Salt TE, Munro PM, Moss SE, Khaw PT. In vitro characterization 
of a spontaneously immortalized human Muller cell line (MIO-M1). Invest 
Ophthalmol.Vis.Sci. 2002;43:864-9.
159
Ling EA. A light microscopic demonstration of amoeboid microglia and 
microglial cells in the retina of rats of various ages. Arch Histol.Jpn. 
1982;45:37-44.
Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic 
potential correlates with enzymatic degradation of basement membrane 
collagen. Nature 1980;284:67-8.
Loeffler KU, Li ZL, Fishman GA, Tso MO. Dominantly inherited cystoid 
macular edema. A histopathologic study. Ophthalmology 1992;99:1385-
92.
Machemer R, Aaberg TM, Freeman HM, Irvine AR, Lean JS, Michels RM. 
An updated classification of retinal detachment with proliferative 
vitreoretinopathy. Am.J.Ophthalmol 1991;112:159-65.
Magistretti PJ, Pellerin L. Astrocytes Couple Synaptic Activity to Glucose 
Utilization in the Brain. News Physiol Sci. 1999;14:177-82.
Mamballikalathil I, Mann C, Guidry C. Tractional force generation by 
porcine Muller cells: paracrine stimulation by retinal pigment epithelium. 
Invest Ophthalmol Vis.Sci. 2000;41:529-36.
Mannion RJ, Costigan M, Decosterd I, Amaya F, Ma QP, Holstege JC et 
al. Neurotrophins: peripherally and centrally acting modulators of tactile
160
stimulus-induced inflammatory pain hypersensitivity.
Proc. Natl. Acad. Sci. U. S. A 1999;96:9385-90.
Manschot WA. Pathology of hereditary juvenile retinoschisis. Arch 
Ophthalmol 1972;88:131-8.
Mansour-Robaey S, Clarke DB, Wang YC, Bray GM, Aguayo AJ. Effects 
of ocular injury and administration of brain-derived neurotrophic factor on 
survival and regrowth of axotomized retinal ganglion cells.
Proc.Natl.Acad. Sci. U.S.A 1994;91:1632-6.
Mantych GJ, Hageman GS, DevaskarSU. Characterization of glucose 
transporter isoforms in the adult and developing human eye. 
Endocrinology 1993;133:600-7.
Marshall J, Bird AC. A comparative histopathological study of argon and 
krypton laser irradiations of the human retina. Br.J. Ophthalmol 
1979;63:657-68.
Martin-Zanca D, Barbacid M, Parada LF. Expression of the trk proto­
oncogene is restricted to the sensory cranial and spinal ganglia of neural 
crest origin in mouse development. Genes Dev. 1990;4:683-94.
Martini B, Ryan SJ. Argon laser lesions of the retina; occurrence and 
origin of macrophages. Eur.J.Ophthalmol 1992;2:51-7.
161
Maxwell P, Salnikow K. HIF-1: an oxygen and metal responsive 
transcription factor. Cancer Biol. Ther. 2004;3:29-35.
Maxwell PH, Ratcliffe PJ. Oxygen sensors and angiogenesis. Semin.Cell 
Dev.Biol. 2002;13:29-37.
McDonald NQ, Lapatto R, Murray-Rust J, Gunning J, Wlodawer A, 
Blundell TL. New protein fold revealed by a 2.3-A resolution crystal 
structure of nerve growth factor. Nature 1991 ;354:411-4.
McDonald NQ, Chao MV. Structural determinants of neurotrophin action. 
J.Biol.Chem. 1995;270:19669-72.
McGillem GS, Guidry C, Dacheux RF. Antigenic changes of rabbit retinal 
Muller cells in culture. Invest Ophthalmol. Vis.Sci. 1998;39:1453-61.
Mey J, Thanos S. Intravitreal injections of neurotrophic factors support the 
survival of axotomized retinal ganglion cells in adult rats in vivo. Brain 
Res. 1993;602:304-17.
Meyer-Franke A, Kaplan MR, Pfrieger FW, Barres BA. Characterization of 
the signaling interactions that promote the survival and growth of 
developing retinal ganglion cells in culture. Neuron 1995;15:805-19.
Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. 
Systemic bevacizumab (Avastin) therapy for neovascular age-related
162
macular degeneration twelve-week results of an uncontrolled open-label 
clinical study. Ophthalmology 2005;112:1035-47.
Middlemas DS, Lindberg RA, Hunter T. trkB, a neural receptor protein- 
tyrosine kinase: evidence for a full-length and two truncated receptors. 
Mol.Cell Biol. 1991;11:143-53.
Miyake Y, Shiroyama N, Ota I, Horiguchi M. Focal macular 
electroretinogram in X-linked congenital retinoschisis. Invest Ophthalmol 
Vis.Sci. 1993;34:512-5.
Moretto G, Xu RY, Walker DG, Kim SU. Co-expression of mRNA for 
neurotrophic factors in human neurons and glial cells in culture. 
J.Neuropathol.Exp.Neurol. 1994;53:78-85.
Morino I, Hiscott P, McKechnie N, Grierson I. Variation in epiretinal 
membrane components with clinical duration of the proliferative tissue. 
Br.J.Ophthalmol 1990;74:393-9.
Musser GL, Rosen S. Localization of carbonic anhydrase activity in the 
vertebrate retina. Exp.Eye Res. 1973;15:105-19.
Nakamura K, Martin KC, Jackson JK, Beppu K, Woo CW, Thiele CJ. 
Brain-derived neurotrophic factor activation of TrkB induces vascular 
endothelial growth factor expression via hypoxia-inducible factor-1 alpha in 
neuroblastoma cells. Cancer Res. 2006;66:4249-55.
163
Neal M, Cunningham J, Lever I, Pezet S, Malcangio M. Mechanism by 
which brain-derived neurotrophic factor increases dopamine release from 
the rabbit retina. Invest Ophthalmol. Vis.Sci. 2003;44:791-8.
Newman EA. Regional specialization of retinal glial cell membrane. Nature 
1984;309:155-7.
Newman EA. Inward-rectifying potassium channels in retinal glial (Muller) 
cells. J.Neurosci. 1993;13:3333-45.
Ng EW, Adamis AP. Anti-VEGF aptamer (pegaptanib) therapy for ocular 
vascular diseases. Ann.N.Y.Acad.Sci. 2006;1082:151-71.
Nicolai U, Eckardt C. The occurrence of macrophages in the retina and 
periretinal tissues in ocular diseases. GerJ.Ophthalmol 1993;2:195-201.
Nilius B, Reichenbach A. Efficient K+ buffering by mammalian retinal glial 
cells is due to cooperation of specialized ion channels. Pflugers Arch. 
1988;411:654-60.
Nykjaer A, Willnow TE, Petersen CM. p75NTR--live or let die.
Curr. Opin.Neurobiol. 2005;15:49-57.
Ogata N, Nishikawa M, Nishimura T, Mitsuma Y, Matsumura M. 
Unbalanced vitreous levels of pigment epithelium-derived factor and
164
vascular endothelial growth factor in diabetic retinopathy.
Am.J.Ophthalmol. 2002;134:348-53.
Ogden T. In: Ryan SJOT, ed. Retina. St Louis: C.V. Mosby, 1989: 32.
Ogden T. In: Ryan SJOT, ed. Retina. St Louis: C.V. Mosby, 1989: 53.
Oku H, Ikeda T, Honma Y, Sotozono C, Nishida K, Nakamura Y et al. 
Gene expression of neurotrophins and their high-affinity Trk receptors in 
cultured human Muller cells. Ophthalmic Res. 2002;34:38-42.
Osborne NN, Block F, Sontag KH. Reduction of ocular blood flow results 
in glial fibrillary acidic protein (GFAP) expression in rat retinal Muller cells. 
Vis.Neurosci. 1991;7:637-9.
Park JE, Keller GA, Ferrara N. The vascular endothelial growth factor 
(VEGF) isoforms: differential deposition into the subepithelial extracellular 
matrix and bioactivity of extracellular matrix-bound VEGF. Mol.Biol.Cell 
1993;4:1317-26.
Peachey NS, Fishman GA, Derlacki DJ, Brigell MG. Psychophysical and 
electroretinographic findings in X-linked juvenile retinoschisis. Arch 
Ophthalmol 1987;105:513-6.
Peinado-Ramon P, Salvador M, Villegas-Perez MP, Vidal-Sanz M. Effects 
of axotomy and intraocular administration of NT-4, NT-3, and brain-
165
derived neurotrophic factor on the survival of adult rat retinal ganglion 
cells. A quantitative in vivo study. Invest Ophthalmol Vis.Sci. 1996;37:489- 
500.
Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE. Vascular endothelial 
growth factor/vascular permeability factor expression in a mouse model of 
retinal neovascularization. Proc.Natl.Acad.Sci.il.S.A 1995;92:905-9.
Pierce GF, Mustoe TA, Lingelbach J, Masakowski VR, Griffin GL, Senior 
RM et al. Platelet-derived growth factor and transforming growth factor- 
beta enhance tissue repair activities by unique mechanisms. J.Cell Biol. 
1989;109:429-40.
Pierce GF, Mustoe TA, Altrock BW, Deuel TF, Thomason A. Role of 
platelet-derived growth factor in wound healing. J.Cell Biochem. 
1991;45:319-26.
Poitry-Yamate CL, Poitry S, Tsacopoulos M. Lactate released by Muller 
glial cells is metabolized by photoreceptors from mammalian retina. 
J.Neurosci. 1995,15:5179-91.
Poitry S, Poitry-Yamate C, Ueberfeld J, MacLeish PR, Tsacopoulos M. 
Mechanisms of glutamate metabolic signaling in retinal glial (Muller) cells. 
J.Neurosci. 2000;20:1809-21.
166
Polk TD, Gass JD, Green WR, Novak MA, Johnson MW. Familial internal 
limiting membrane dystrophy. A new sheen retinal dystrophy.
Arch.Ophthalmol. 1997;115:878-85.
Potts RA, Dreher B, Bennett MR. The loss of ganglion cells in the 
developing retina of the rat. Brain Res. 1982;255:481-6.
Pow DV, Robinson SR. Glutamate in some retinal neurons is derived 
solely from glia. Neuroscience 1994;60:355-66.
Price RL, Haley ST, Bullard TA, Goldsmith EC, Simpson DG, Thielen TE 
et al. Effects of platelet-derived growth factor-AA and -BB on embryonic 
cardiac development. Anat.Rec.A Discov.Mol.Cell EvoiBiol. 
2003;272:424-33.
Raju TR, Bennett MR. Retinal ganglion cell survival requirements: a major 
but transient dependence on Muller glia during development. Brain Res. 
1986;383:165-76.
Rasmussen KE. The Muller cell: a comparative study of rod and cone 
retinas with and without retinal vessels. Exp.Eye Res. 1974;19:243-57.
Reichardt LF, Farinas I. In: Cowan WM JTZS, ed. Molecular and Cellular 
Approaches to Neural Development. Oxford University Press , 1997: 220- 
63.
167
Reichenbach A, Schneider H, Leibnitz L, Reichelt W, Schaaf P,
Schumann R. The structure of rabbit retinal Muller (glial) cells is adapted 
to the surrounding retinal layers. Anat.Embryol.(Berl) 1989;180:71-9.
Reichenbach A, Henke A, Eberhardt W, Reichelt W, Dettmer D. K+ ion 
regulation in retina. Can.J.Physiol Pharmacol. 1992;70 Suppl:S239-S247.
Reichenbach, A. and Robinson, S. R. phylogenic constraints on retinal 
organization and development
59. Osborne, N. N. and Chader, G. J. (15), 139-171. 1995. Oxford, 
Pergamon. Progress in Retinal and Eye Research.
Ref Type: Serial (Book,Monograph)
Reid SN, Farber DB. Glial transcytosis of a photoreceptor-secreted 
signaling protein, retinoschisin. Glia 2005;49:397-406.
Rickman DW, Brecha NC. Expression of the proto-oncogene, trk, 
receptors in the developing rat retina. Vis.Neurosci. 1995;12:215-22.
Riepe RE, Norenburg MD. Muller cell localisation of glutamine synthetase 
in rat retina. Nature 1977;268 :654-5.
Ringstedt T, Ibanez CF, Nosrat CA. Role of brain-derived neurotrophic 
factor in target invasion in the gustatory system. J.Neurosci. 
1999;19:3507-18.
168
Robinson RC, Radziejewski C, Stuart Dl, Jones EY. Structure of the brain- 
derived neurotrophic factor/neurotrophin 3 heterodimer. Biochemistry 
1995;34:4139-46.
Robinson RC, Radziejewski C, Spraggon G, Greenwald J, Kostura MR, 
Burtnick LD et al. The structures of the neurotrophin 4 homodimer and the 
brain-derived neurotrophic factor/neurotrophin 4 heterodimer reveal a 
common Trk-binding site. Protein Sci. 1999;8:2589-97.
Robinson SR, Dreher Z. Muller cells in adult rabbit retinae: morphology, 
distribution and implications for function and development. J.Comp Neurol. 
1990;292:178-92.
Rodrigues MM, Newsome DA, Machemer R. Further characterization of 
epiretinal membranes in human massive periretinal proliferation. Curr.Eye 
Res. 1981;1:311-5.
Roque RS, Agarwal N, Wordinger RJ, Brun AM, Xue Y, Huang LC et al. 
Human papillomavirus-16 E6/E7 transfected retinal cell line expresses the 
Muller cell phenotype. Exp.Eye Res. 1997;64:519-27.
Rose CR, Blum R, Pichler B, Lepier A, Kafitz KW, Konnerth A. Truncated 
TrkB-T1 mediates neurotrophin-evoked calcium signalling in glia cells. 
Nature 2003;426:74-8.
169
Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography 
findings after an intravitreal injection of bevacizumab (avastin) for 
neovascular age-related macular degeneration. Ophthalmic Surg.Lasers 
Imaging 2005;36:331-5.
Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et 
al. Ranibizumab for neovascular age-related macular degeneration. 
N.Engl.J.Med. 2006;355:1419-31.
Roth S. Role of nitric oxide in retinal cell death. Clin.Neurosci. 1997;4:216- 
23.
Saari JC, Futterman S, Bredberg L. Cellular retinol- and retinoic acid- 
binding proteins of bovine retina. Purification and properties. J.Biol.Chem. 
1978;253:6432-6.
Saari JC, Bredberg L, Garwin GG. Identification of the endogenous 
retinoids associated with three cellular retinoid-binding proteins from 
bovine retina and retinal pigment epithelium. J.Biol.Chem. 
1982;257:13329-33.
Sarthy V, Ripps H. In: Blakemore C, ed. The retinal Muller cell, structure 
and function. Kluwer academic/plenum, 2001: 217-24.
170
Sarthy VP, Brodjian SJ, Dutt K, Kennedy BN, French RP, Crabb JW. 
Establishment and characterization of a retinal Muller cell line. Invest 
Ophthalmol. Vis.Sci. 1998;39:212-6.
Sauer CG, Gehrig A, Warneke-Wittstock R, Marquardt A, Ewing CC, 
Gibson A et al. Positional cloning of the gene associated with X-linked 
juvenile retinoschisis. Nat.Genet. 1997;17:164-70.
Schatteman GC, Gibbs L, Lanahan AA, Claude P, Bothwell M. Expression 
of NGF receptor in the developing and adult primate central nervous 
system. J.Neurosci. 1988;8:860-73.
Schnitzer J. Immunocytochemical studies on the development of 
astrocytes, Muller (glial) cells, and oligodendrocytes in the rabbit retina. 
Brain Res.Dev.Brain Res. 1988;44:59-72.
Schwartz D, de la Cruz ZC, Green WR, Michels RG. Proliferative 
vitreoretinopathy. Ultra structural study of 20 retroretinal membranes 
removed by vitreous surgery. Retina 1988;8:275-81.
Segal RA, Greenberg ME. Intracellular signaling pathways activated by 
neurotrophic factors. Annu.Rev.Neurosci. 1996;19:463-89.
Segal RA, Greenberg ME. Intracellular signaling pathways activated by 
neurotrophic factors. Annu.Rev.Neurosci. 1996;19:463-89.
171
Seidah NG, Benjannet S, Pareek S, Chretien M, Murphy RA. Cellular 
processing of the neurotrophin precursors of NT3 and BDNF by the 
mammalian proprotein convertases. FEBS Lett. 1996;379:247-50.
Shelton DL, Sutherland J, Gripp J, Camerato T, Armanini MP, Phillips HS 
et al. Human trks: molecular cloning, tissue distribution, and expression of 
extracellular domain immunoadhesins. J.Neurosci. 1995;15:477-91.
Sheng M, McFadden G, Greenberg ME. Membrane depolarization and 
calcium induce c-fos transcription via phosphorylation of transcription 
factor CREB. Neuron 1990;4:571-82.
Sigelman J, Ozanics V. In: Jakobiec F, ed. ocular anatomy, embryology, 
and teratology. Philadelphia: Harper and Row, 1982: 441.
Smith-Thomas L, Richardson P, Parsons MA, Rennie IG, Benson M, 
MacNeil S. Additive effects of extra cellular matrix proteins and platelet 
derived mitogens on human retinal pigment epithelial cell proliferation and 
contraction. Curr.Eye Res. 1996;15:739-48.
Soppet D, Escandon E, Maragos J, Middlemas DS, Reid SW, Blair J et al. 
The neurotrophic factors brain-derived neurotrophic factor and 
neurotrophin-3 are ligands for the trkB tyrosine kinase receptor. Cell 
1991;65:895-903.
172
Squinto SP, Stitt TN, Aldrich TH, Davis S, Bianco SM, Radziejewski C et 
al. trkB encodes a functional receptor for brain-derived neurotrophic factor 
and neurotrophin-3 but not nerve growth factor. Cell 1991;65:885-93.
Steinberg RH. Survival factors in retinal degenerations.
Curr. Opin.Neurobiol. 1994;4:515-24.
Stone J, Dreher Z. Relationship between astrocytes, ganglion cells and 
vasculature of the retina. J.Comp Neurol. 1987;255:35-49.
Strausberg RL, Feingold EA, Grouse LH, Derge JG, Klausner RD, Collins 
FS et al. Generation and initial analysis of more than 15,000 full-length 
human and mouse cDNA sequences. Proc.Natl.Acad.Scl.U.S.A 
2002;99:16899-903.
Tafreshi AP, Zhou XF, Rush RA. Endogenous nerve growth factor and 
neurotrophin-3 act simultaneously to ensure the survival of postnatal 
sympathetic neurons in vivo. Neuroscience 1998;83:373-80.
The Retinoschisis Consortium. Functional implications of the spectrum of 
mutations found in 234 cases with X-linked juvenile retinoschisis.
Hum.Mol.Genet. 1998;7:1185-92.
Thoenen H, Sendtner M. Neurotrophins: from enthusiastic expectations 
through sobering experiences to rational therapeutic approaches. 
Nat.Neurosci. 2002;5 Suppl:1046-50.
173
Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC et 
al. The human gene for vascular endothelial growth factor. Multiple protein 
forms are encoded through alternative exon splicing. J.Biol.Chem. 
1991;266:11947-54.
Tobe T, Takahashi K, Kishimoto N, Ohkuma H, Uyama M. [Effects of 
interferon-beta on repair of the retinal pigment epithelium after laser 
photocoagulation]. Nippon Ganka Gakkai Zasshi 1995;99:792-805.
Toker A, Cantley LC. Signalling through the lipid products of 
phosphoinositide-3-OH kinase. Nature 1997;387:673-6.
Tomita H, Ishiguro S, Abe T, Tamai M. Increased expression of low-affinity 
NGF receptor in rat retinal Muller cells after ischemia and reperfusion. Cell 
Struct.Funct. 1998;23:201-7.
Trese MT, Chandler DB, Machemer R. Subretinal strands: ultrastructural 
features. Graefes Arch Clin.Exp.Ophthalmol 1985;223:35-40.
Tripathi RC, Tripathi BJ. In: Davson H, ed. The eye. 3rd ed. London: 
Academic press, 1984: 40, 157.
Tso MO. Pathology of cystoid macular edema. Ophthalmology 
1982;89:902-15.
174
Tsoulfas P, Soppet D, Escandon E, Tessarollo L, Mendoza-Ramirez JL, 
Rosenthal A et al. The rat trkC locus encodes multiple neurogenic 
receptors that exhibit differential response to neurotrophin-3 in PC12 cells. 
Neuron 1993;10:975-90.
Uga S. Some structural features of the retinal Mullerian cells in the juxta- 
optic nerve region. Exp.Eye Res. 1974; 19:105-15.
Unoki K, LaVail MM. Protection of the rat retina from ischemic injury by 
brain-derived neurotrophic factor, ciliary neurotrophic factor, and basic 
fibroblast growth factor. Invest Ophthalmol Vis.Sci. 1994;35:907-15.
Valenzuela DM, Maisonpierre PC, Glass DJ, Rojas E, Nunez L, Kong Y et 
al. Alternative forms of rat TrkC with different functional capabilities. 
Neuron 1993;10:963-74.
van derZE, Fankhauser F, Raess K, England C. Morphologic findings in 
the rabbit retina following irradiation with the free-running neodymium- 
YAG laser. Disruption of Bruch's membrane and its effect on the scarring 
process in the retina and choroid. Arch Ophthalmol 1986;104:1070-7.
Van Horn DL, Aaberg TM, Machemer R, Fenzl R. Glial cell proliferation in 
human retinal detachment with massive periretinal proliferation.
Am.J.Ophthalmol 1977;84:383-93.
175
Vecino E, Caminos E, Ugarte M, Martin-Zanca D, Osborne NN. 
Immunohistochemical distribution of neurotrophins and their receptors in 
the rat retina and the effects of ischemia and reperfusion. Gen.Pharmacol. 
1998;30:305-14.
Venero JL, Knusel B, Beck KD, Hefti F. Expression of neurotrophin and trk 
receptor genes in adult rats with fimbria transections: effect of 
intraventricular nerve growth factor and brain-derived neurotrophic factor 
administration. Neuroscience 1994;59:797-815.
von Bartheld CS, Wang X, Butowt R. Anterograde axonal transport, 
transcytosis, and recycling of neurotrophic factors: the concept of trophic 
currencies in neural networks. Mol.Neurobiol. 2001;24:1-28.
Vrabec F. Microglia in the monkey and rabbit retina.
J.Neuropathol. Exp. Neurol. 1970,29:217-24.
Wahlin KJ, Campochiaro PA, Zack DJ, Adler R. Neurotrophic factors 
cause activation of intracellular signaling pathways in Muller cells and 
other cells of the inner retina, but not photoreceptors. Invest 
Ophthalmol. Vis.Sci. 2000;41:927-36.
Watanabe T, Mio Y, Hoshino FB, Nagamatsu S, Hirosawa K, Nakahara K. 
GLUT2 expression in the rat retina: localization at the apical ends of 
Muller cells. Brain Res. 1994;655:128-34.
176
Weng G, Bhalla US, Iyengar R. Complexity in biological signaling 
systems. Science 1999;284:92-6.
Wilkes SR, Mansour AM, Green WR. Proliferative vitreoretinopathy. 
Histopathology of retroretinal membranes. Retina 1987;7:94-101.
Winter M, Eberhardt W, Scholz C, Reichenbach A. Failure of potassium 
siphoning by Muller cells: a new hypothesis of perfluorocarbon liquid- 
induced retinopathy. Invest Ophthalmol. Vis.Sci. 2000;41:256-61.
Wolter JR. Glia of the human retina. Am.J.Ophthalmol 1959;48(5)Pt 
2:370-93.
Wolter JR. The histopathology of cystoid macular edema.
Albrecht Von. Graefes Arch.Klin.Exp. Ophthalmol. 1981 ;216:85-101.
Wordinger RJ, Lambert W, Agarwal R, Talati M, Clark AF. Human 
trabecular meshwork cells secrete neurotrophins and express 
neurotrophin receptors (Trk). Invest Ophthalmol Vis.Sci. 2000;41:3833-41.
Xiao M, McLeod D, Cranley J, Williams G, Boulton M. Growth factor 
staining patterns in the pig retina following retinal laser photocoagulation. 
Br.J.Ophthalmol 1999;83:728-36.
Yamamoto H, Gurney ME. Human platelets contain brain-derived 
neurotrophic factor. J.Neurosci. 1990;10:3469-78.
177
Yang R, Thomas GR, Bunting S, Ko A, Ferrara N, Keyt B et al. Effects of 
vascular endothelial growth factor on hemodynamics and cardiac 
performance. J.Cardiovasc.Pharmacol. 1996;27:838-44.
Yanoff M, Kertesz RE, Zimmerman LE. Histopathology of juvenile 
retinoschisis. Arch Ophthalmol 1968;79:49-53.
Yanoff M, Fine BS, Brucker AJ, Eagle RC, Jr. Pathology of human cystoid 
macular edema. Surv.Ophthalmol. 1984;28 Suppl:505-11.
Zanellato A, Comelli MC, Dal Toso R, Carmignoto G. Developing rat 
retinal ganglion cells express the functional NGF receptor p140trkA.
Dev. Biol. 1993;159:105-13.
Zheng Y, Ikuno Y, Ohj M, Kusaka S, Jiang R, Cekic O et al. Platelet- 
derived growth factor receptor kinase inhibitor AG1295 and inhibition of 
experimental proliferative vitreoretinopathy. Jpn.J.Ophthalmol. 
2003;47:158-65.
Zhou XF, Cameron D, Rush RA. Endogenous neurotrophin-3 supports the 
survival of a subpopulation of sensory neurons in neonatal rat. 
Neuroscience 1998;86:1155-64.
178
